ANGEION CORP/MN, 424B1, 1996-07-02

ANGEION CORP/MN
424B1, 1996-07-02
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Previous: QUADRAX CORP, 8-K, 1996-07-02

Next: CARNIVAL CORP, 10-Q, 1996-07-02

4,200,000 SHARES

ANGEION LOGO

COMMON STOCK

THE 4,200,000 SHARES OF COMMON STOCK, PAR VALUE $0.01 PER SHARE (THE "SHARES"),
OFFERED HEREBY ARE BEING ISSUED AND SOLD BY ANGEION CORPORATION ("ANGEION" OR
THE "COMPANY"). THE COMMON STOCK OF THE COMPANY IS TRADED ON THE NASDAQ NATIONAL
MARKET UNDER THE SYMBOL "ANGN." ON JULY 1, 1996, THE LAST REPORTED SALE PRICE OF
THE COMMON STOCK ON THE NASDAQ NATIONAL MARKET WAS $7.50.

SEE"RISK FACTORS" BEGINNING ON PAGE 6 FOR A DISCUSSION OF CERTAIN FACTORS
THAT SHOULD BE CONSIDERED BY PROSPECTIVE INVESTORS.

THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMIS- SION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

<TABLE>
<CAPTION>
UNDERWRITING
PRICE TO DISCOUNTS AND PROCEEDS TO
PUBLIC COMMISSIONS(1) COMPANY(2)
<S> <C> <C> <C>
Per Share $7.00 $0.4025 $6.5975
Total(3) $29,400,000 $1,690,500 $27,709,500
</TABLE>

(1) The Company has agreed to indemnify the Underwriters against certain
liabilities, including liabilities under the Securities Act of 1933, as
amended (the "Securities Act"). See "Underwriting."

(2) Before deducting estimated offering expenses of $250,000, which are
payable by the Company.

(3) The Company has granted to the Underwriters a 30-day option to purchase
up to 630,000 additional shares of Common Stock on the same terms and
conditions as the securities offered hereby solely to cover
over-allotments, if any. If the option is exercised in full, the Price to
Public, Underwriting Discounts and Commissions and Proceeds to Company
will be $33,810,000, $1,944,075 and $31,865,925, respectively. See
"Underwriting."

THE SHARES OF COMMON STOCK ARE OFFERED SEVERALLY BY THE UNDERWRITERS SUBJECT TO
PRIOR SALE, WHEN, AS AND IF DELIVERED TO AND ACCEPTED BY THEM, AND SUBJECT TO
CERTAIN OTHER CONDITIONS INCLUDING THE RIGHT OF THE UNDERWRITERS TO WITHDRAW,
CANCEL, MODIFY OR REJECT ANY ORDER IN WHOLE OR IN PART. IT IS EXPECTED THAT
DELIVERY OF THE SHARES OF THE COMMON STOCK WILL BE MADE AT THE OFFICES OF
RAYMOND JAMES & ASSOCIATES, INC., ST. PETERSBURG, FLORIDA ON OR ABOUT JULY 8,
1996.

RAYMOND JAMES & ASSOCIATES, INC.

NATWEST SECURITIES LIMITED
SALOMON BROTHERS INC

The date of this Prospectus is July 1, 1996.

Inside Front Cover:

1. Illustration: Internal view of heart of a patient showing the placement of
the ICD in the pectoral region of the body and the leads threaded into the
vein and into the ventricle of the heart. Two sketches surround
illustration depicting the Defibrillation test system and programmer in
use during implant and a follow-up visit at the physician's office using
the programmer/interrogator.

2. Two page spread; background - mechanical illustrations of RF, laser
catheter, Sentinel ICD cues and headers.

A. Center illustration of cross section of a heart depicting the
chambers and electrical pathways of the heart.

3. Photo of ICD system including ICD, computer programmer, Defibrillation
test system, smart wand and transvenous leads.

4. Photo of 3 models of Sentinel ICD.

5. Closeup photo of tip of radio frequency ablation catheter.

6. Closeup photo of tip of laser ablation catheter.

FOR UNITED KINGDOM PURCHASERS: THE COMMON STOCK MAY NOT BE OFFERED OR SOLD
IN THE UNITED KINGDOM OTHER THAN TO PERSONS WHOSE ORDINARY ACTIVITIES INVOLVE
THEM IN ACQUIRING, HOLDING, MANAGING OR DISPOSING OF INVESTMENTS, WHETHER AS
PRINCIPAL OR AGENT (EXCEPT IN CIRCUMSTANCES THAT DO NOT CONSTITUTE AN OFFER TO
THE PUBLIC WITHIN THE MEANING OF THE PUBLIC OFFERS OF SECURITIES REGULATIONS
1995 OR THE FINANCIAL SERVICES ACT 1986), AND THIS PROSPECTUS MAY ONLY BE ISSUED
OR PASSED ON TO ANY PERSON IN THE UNITED KINGDOM IF THAT PERSON IS OF A KIND
DESCRIBED IN ARTICLE 11(3) OF THE FINANCIAL SERVICES ACT 1986 (INVESTMENT
ADVERTISEMENTS) (EXEMPTIONS) ORDER 1995 OR IS A PERSON TO WHOM THE PROSPECTUS
MAY OTHERWISE LAWFULLY BE PASSED ON.

IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER- ALLOT OR
EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON
STOCK OF THE COMPANY AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE
OPEN MARKET. SUCH TRANSACTIONS MAY BE EFFECTED ON THE NASDAQ NATIONAL MARKET, IN
THE OVER-THE-COUNTER MARKET OR OTHERWISE. SUCH STABILIZING, IF COMMENCED, MAY BE
DISCONTINUED AT ANY TIME.

IN CONNECTION WITH THIS OFFERING, CERTAIN UNDERWRITERS AND SELLING GROUP
MEMBERS (IF ANY) OR THEIR RESPECTIVE AFFILIATES MAY ENGAGE IN PASSIVE MARKET
MAKING TRANSACTIONS IN THE COMPANY'S COMMON STOCK ON THE NASDAQ NATIONAL MARKET
IN ACCORDANCE WITH RULE 10b-6A UNDER THE SECURITIES EXCHANGE ACT OF 1934. SEE
"UNDERWRITING."

SUMMARY

THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY THE MORE DETAILED
INFORMATION AND FINANCIAL STATEMENTS AND NOTES THERETO CONTAINED ELSEWHERE OR
INCORPORATED BY REFERENCE IN THIS PROSPECTUS. INVESTORS SHOULD CAREFULLY
CONSIDER THE INFORMATION SET FORTH UNDER THE HEADING "RISK FACTORS." UNLESS
OTHERWISE INDICATED, ALL INFORMATION CONTAINED IN THIS PROSPECTUS ASSUMES NO
EXERCISE OF THE UNDERWRITERS' OVER-ALLOTMENT OPTION.

THE COMPANY

Angeion Corporation designs, develops and manufactures products that treat
irregular heartbeats (arrhythmias). The Company is developing the SENTINEL
series of implantable cardioverter defibrillators ("ICDs"), which it believes
are among the smallest and most technologically advanced ICDs currently in
clinical trials or market-approved. ICDs are designed to treat abnormally rapid
heartbeats in the ventricular (or lower) chambers of the heart, a condition
known as ventricular tachycardia ("VT"), and a severe form of VT known as
ventricular fibrillation ("VF"), which if not terminated will lead to sudden
cardiac death ("SCD"). ICDs are electronic devices that are implanted within the
body and are connected to the heart with defibrillator leads. These devices
monitor the patient's heartbeat and, in the event of VT or VF, deliver an
electrical shock to return the heartbeat to normal rhythm. Following receipt of
an Investigational Device Exemption ("IDE") from the U.S. Food and Drug
Administration ("FDA"), the Company commenced U.S. clinical trials of its first
SENTINEL model, the SENTINEL 2000, in March 1996. In April 1996, the Company
received CE Mark approval to market the SENTINEL 2000 in the European Union
("EU"). Based on its clinical trial progress to date, the Company plans to
submit its application for Pre-Market Approval ("PMA") for the SENTINEL 2000 and
the SENTINEL 2010 series to the FDA in the first half of calendar 1997.

The worldwide market for ICDs and defibrillator leads has grown from $160
million in 1990 to over $650 million in 1995, representing a compounded annual
growth rate in excess of 30%. It is estimated that in 1995 approximately 25,000
ICDs were implanted worldwide. The ICD market is expected to continue to grow at
an annual rate of approximately 20% to reach a worldwide market size of
approximately $1.3 billion by the end of the decade. The growth rate for this
market is attributable to a number of factors, including: (i) expansion of the
indications for use of an ICD; (ii) smaller devices allowing for less invasive
and less costly surgical procedures; (iii) less effective performance of drug
therapy compared with ICDs; (iv) an increasing survival rate for SCD episodes;
and (v) rapidly advancing ICD technology.

The Company believes the SENTINEL series of ICDs offers certain benefits over
competitors' ICDs currently in clinical trials or market-approved, including
reduced size and weight, increased longevity and greater flexibility in
treatment options. These benefits are derived from the Company's proprietary
product features and technologies, including: (i) its dual battery system; (ii)
a more efficient biphasic waveform that lowers defibrillation energy thresholds;
(iii) the HOT CAN electrode system, which uses the SENTINEL housing as an
electrode that can be programmed on and off; and (iv) an energy delivery system
that permits the ICD to increase shock effectiveness by directing the current
more uniformly throughout the heart.

The Company is also developing a radio frequency ("RF") catheter ablation system
that it believes offers a potential cure for certain forms of atrial arrhythmias
(rapid heartbeats originating in the upper chambers of the heart) and a laser
catheter ablation system that it believes offers a potential cure for certain
forms of VT. The Company has received an IDE from the FDA for both its RF and
laser catheter ablation systems. The Company plans to commence clinical trials
for its RF catheter ablation systems and to expand clinical trials for its laser
catheter ablation systems during the second half of calendar 1996.

Although the market for catheter ablation devices in the treatment of
arrhythmias is much less defined and in an earlier stage of development than the
ICD market, the worldwide ablation market has grown to approximately 110,000
procedures in 1995, primarily for the treatment of one form of atrial arrhythmia
known as supraventricular tachycardia ("SVT"). If cardiac ablation becomes an
accepted treatment for atrial fibrillation, atrial flutter or VT, the aggregate
market for cardiac ablation could further increase. The following factors are
driving the growth of this market: (i) catheter ablation offers a potential cure
for certain forms of arrhythmia rather than simply managing its symptoms; (ii)
catheter ablation is a cost-effective, minimally invasive procedure; and (iii)
advancements in electrophysiology mapping technology, known as "global mapping,"
are expected to allow more effective identification of the source of the
arrhythmia.

The Company believes its ablation products offer distinct advantages over
competitive products and techniques currently in clinical trials or
market-approved. The Company's RF catheter ablation system uses a proprietary
saline-cooled porous metal tip that prevents the formation of coagulum during
the ablation procedure and delivers the energy into the tissue more efficiently.
The Company's RF catheter ablation system is designed to treat SVT. Future
models of this catheter are being designed to treat other atrial arrhythmias,
such as atrial flutter and atrial fibrillation. Because the ventricular wall
(muscle) is too thick to be fully penetrated by RF energy, the Company intends
to address ventricular arrhythmias, such as VT, with the application of laser
energy.

The Company intends to market and sell its ICD and catheter ablation products on
a worldwide basis through three channels: (i) a direct Company sales force in
the United States; (ii) direct sales representatives and independent
distributors outside the United States; and (iii) its strategic alliance with
Pacesetter, Inc. ("Pacesetter"), one of the largest cardiovascular distribution
networks in the world and a subsidiary of St. Jude Medical, Inc. In preparation
for product launch of the SENTINEL 2000 in Europe, the Company has formed a
European subsidiary and established distributorships or direct sales
representation in a number of European countries. The Company's manufacturing
facility in Minneapolis, Minnesota and the facility of the Company's contract
manufacturer in Scotland have received ISO 9002 certification.

The Company's objective is to build a full line of electrophysiology products
for the treatment and cure of cardiac arrhythmias. The Company's strategy is to
focus on one area of cardiovascular disease, cardiac arrhythmias, and one common
practitioner, the electrophysiologist. In pursuit of its strategy, the Company
has developed innovative ICD and catheter ablation technologies; assembled a
management, research, engineering and medical team with significant medical
device industry experience; built what it believes to be a strong patent
portfolio; and entered into a strategic alliance with Pacesetter to provide
timely access to worldwide markets.

The Company was incorporated in Minnesota in May 1986. The Company's principal
executive offices are located at 3650 Annapolis Lane, Suite 170, Minneapolis,
Minnesota 55447-5434, and its telephone number at that location is (612)
550-9388.

ANGEION(R), SENTINEL(tm), SMALL CAP(tm), HOT CAN(tm), ENERGY STEERING(tm), SMART
WAND(tm), TUNED(tm), ANGEPASS(tm), ANGEPORE(tm), and ANGEFLEX(tm) are trademarks
of the Company. All other trademarks and trade names used herein are the
property of their respective owners.

THE OFFERING

Common Stock Offered .............. 4,200,000 shares

Common Stock to be Outstanding
after the Offering (1) ............ 28,412,207 shares
Use of Proceeds ................... Expansion of clinical trials,
research and development, scale-up and
expansion of manufacturing and marketing
activities, potential acquisitions and
general corporate purposes, including
working capital.

Nasdaq National Market Symbol ..... ANGN

(1) Based on the number of shares of Common Stock outstanding on April 30,
1996. Does not include 3,425,066 shares issuable upon the exercise of
outstanding options and warrants and 1,125,000 shares issuable upon
conversion of the Series A Preferred Stock and a convertible debenture.
See "Description of Securities."

SUMMARY FINANCIAL DATA

<TABLE>
<CAPTION>
YEAR ENDED JULY 31, NINE MONTHS ENDED APRIL 30,
1993 1994 1995 1995 1996
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net sales $ 137,982 $ 0 $ 0 $ 0 $ 874,959
Manufacturing expenses (1) 147,755 0 0 0 2,278,242
Research and development 4,485,818 5,158,738 7,815,391 5,268,028 6,717,469
Sales and marketing (2) 0 0 0 12,767 387,634
General and administrative 1,353,502 1,460,424 1,849,376 1,495,868 2,444,543
Net loss (3) $(2,708,438) $(7,675,743) $(9,643,351) $(6,673,157) $(10,161,744)
Net loss per share (3)(4) $ (0.26) $ (0.72) $ (0.58) $ (0.41) $ (0.46)
Weighted average number of
shares outstanding (4) 10,296,812 10,657,311 16,550,915 16,291,900 21,953,593
</TABLE>

<TABLE>
<CAPTION>
APRIL 30, 1996
ACTUAL AS ADJUSTED (5)
<S> <C> <C>
BALANCE SHEET DATA:
Cash and cash equivalents $ 14,789,510 $ 42,249,010
Short-term investments 7,328,201 7,328,201
Working capital 22,953,009 50,412,509
Total assets 30,572,968 58,032,468
Long-term debt, less current
installments 1,500,000 1,500,000
Accumulated deficit (37,347,476) (37,347,476)
Shareholders' equity 26,445,804 53,905,304
</TABLE>

(1) The amounts reflected in manufacturing expenses for the year ended July 31,
1993 and the nine months ended April 30, 1996 reflect cost of goods sold for
those periods.

(2) Sales and marketing for the years ended July 31, 1993 through 1995 is
included in general and administrative.

(3) Net loss and net loss per share for the year ended July 31, 1993 reflect a
gain on sale of discontinued operations of $3,207,120, or $0.31 per share,
resulting from the sale of the Angeion Medical Products division ("AMP").

(4) Computed on the basis described for net loss per share in Note 2 of Notes to
Financial Statements.

(5) Adjusted to give effect to the sale of the Shares offered hereby at a per
share offering price of $7.00 and application of the estimated net
proceeds therefrom. See "Use of Proceeds."

RISK FACTORS

THE SHARES OFFERED HEREBY INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE RISKS
DESCRIBED BELOW. PROSPECTIVE INVESTORS SHOULD CAREFULLY CONSIDER THE FOLLOWING
RISK FACTORS TOGETHER WITH THE OTHER INFORMATION CONTAINED IN THIS PROSPECTUS
BEFORE PURCHASING THE SHARES OFFERED HEREBY.

THIS PROSPECTUS CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS. FOR THIS PURPOSE,
ANY STATEMENTS CONTAINED IN THIS PROSPECTUS THAT ARE NOT STATEMENTS OF
HISTORICAL FACT MAY BE DEEMED TO BE FORWARD-LOOKING STATEMENTS. WITHOUT LIMITING
THE FOREGOING, WORDS SUCH AS "MAY," "WILL," "EXPECT," "BELIEVE," "ANTICIPATE,"
"ESTIMATE" OR "CONTINUE" OR THE NEGATIVE OR OTHER VARIATIONS THEREOF OR
COMPARABLE TERMINOLOGY ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS.
THESE STATEMENTS BY THEIR NATURE INVOLVE SUBSTANTIAL RISKS AND UNCERTAINTIES,
AND ACTUAL RESULTS MAY DIFFER MATERIALLY DEPENDING ON A VARIETY OF FACTORS,
INCLUDING THOSE DESCRIBED BELOW.

CONTINUING OPERATING LOSSES; PROFITABILITY UNCERTAIN; FLUCTUATIONS IN
OPERATING RESULTS

The Company has incurred net operating losses from continuing operations in each
year since its inception in 1986. At April 30, 1996, the Company's accumulated
deficit was approximately $37.3 million. Losses have resulted principally from
costs incurred in the research and development of the Company's products. The
Company has had no significant revenue since the sale of AMP in September 1992.
The Company expects to incur additional operating losses over the next several
years as the Company continues to fund research and development (including
clinical trials) relating to its ICDs and catheter ablation systems and invests
in building its manufacturing and marketing capabilities. The Company's ability
to achieve profitability is dependent in part on obtaining regulatory approvals
for its products and developing the capacity to manufacture and sell its
products successfully. There can be no assurance that the Company will obtain
the required regulatory approvals on a timely basis, if at all; successfully
develop, commercialize, manufacture and market its products; or achieve
profitability. In addition, the Company's results of operations may fluctuate
significantly from quarter to quarter depending upon a number of factors,
including the availability of third party reimbursement, the timing of
regulatory approvals, progress of product development and clinical trials, the
extent to which the Company's products gain market acceptance, marketing and
manufacturing costs and competition. See "Management's Discussion and Analysis
of Financial Condition and Results of Operations."

IMPACT OF COMPETITION

Competition in the ICD market is intense. Although the Company's ICDs will
also compete with alternative treatments for VT such as drug therapy, open
heart surgery and cardiac ablation, the Company believes that ICD
manufacturers constitute its primary competition. Three companies, Medtronic,
Inc. ("Medtronic"), Cardiac Pacemakers, Inc. ("CPI"), a division of Guidant
Corporation, and Ventritex, Inc. ("Ventritex"), currently have PMA-approved
products in the ICD market and control virtually all of that market today.

Any product developed by the Company that gains regulatory approval will have to
compete for market acceptance and market share. The timing of market
introduction of competitive products could adversely affect the competitiveness
of the Company's products. Accordingly, the relative speed with which the
Company can develop products, complete clinical testing and the regulatory
approval process and supply commercial quantities of the product to the market
are expected to be important competitive factors. The Company expects that
competition will also be based on device size and weight, longevity, ease of
programmability, ability to provide diagnostic capability, product reliability,
physician familiarity with the device, patent protection, sales and marketing
capability, third-party reimbursement policies, reputation and price. There can
be no assurance that FDA approval will be obtained for the Company's ICDs, that
competitors will not introduce new products with similar features or that the
market will accept the SENTINEL series. Most of the Company's competitors in the
ICD market have greater financial, manufacturing, marketing, distribution and
technical resources and greater name recognition than the Company.

Although catheter ablation offers a potential cure, rather than a treatment, of
VT catheter ablation technologies must nonetheless compete with drug therapy,
open heart surgery and ICDs. A number of companies, certain of which have
significantly greater resources than the Company, have developed RF catheter
ablation devices to treat SVT. There can be no assurance that competitors of the
Company will not be able to develop and introduce cardiac ablation systems more
quickly than the Company or systems that may be more effective in treating SVT
and VT than the Company's cardiac ablation systems. In addition, there can be no
assurance that the Company's catheter ablation systems will receive FDA approval
or, if approved, that the market will accept such systems. Catheter ablation
technologies also compete with drug therapy. While historically drug therapy has
had limited effectiveness and caused adverse side effects, new drugs under
development may offer improved treatment outcomes. See "Business --
Competition."

IMPORTANCE OF INTELLECTUAL PROPERTY PROTECTION

Patents and trademarks are critical in the medical device industry. There can be
no assurance that patents and trademarks will be granted to the Company in the
future, or that any patents and trademarks that the Company now holds or may be
granted or under which it has been granted licenses will be adjudicated to be
valid if challenged or otherwise be of value. Even if the Company's patents and
trademarks are granted, others may be able to challenge the validity of such
patents and trademarks or introduce non-infringing products that are competitive
with the Company's products.

There can be no assurance that allegations of infringement of the proprietary
rights of third parties will not be made, or that if made such allegations would
not be sustained if litigated. There has been substantial litigation regarding
patent and other intellectual property rights in the medical device industry,
particularly in the ICD portion. Litigation, which could result in substantial
cost to and diversion of effort by the Company, may be necessary to enforce
patents issued to or licensed by the Company, to protect trade secrets or
technology owned by the Company or to defend the Company against claimed
infringement of the rights of others and to determine the scope and validity of
the proprietary rights of others. Adverse determinations in litigation could
subject the Company to significant liabilities to third parties or could require
the Company to seek licenses from third parties.

Although patent and intellectual property disputes in the medical device area
have often been settled through licensing or similar arrangements, costs
associated with such arrangements may be substantial and there can be no
assurance that necessary licenses would be available to the Company on
satisfactory terms, if at all. Accordingly, an adverse determination in a
judicial or administrative proceeding or failure to obtain necessary licenses
could prevent the Company from manufacturing and selling its products, which
would have a material adverse effect on the Company. The license agreement
currently in existence between the Company and Pacesetter may affect the ability
of the Company to settle any intellectual property disputes related to the
Company's products on reasonable terms, if at all, which could have a material
adverse effect on the Company.

The Company also relies on trade secrets and proprietary technology, which it
seeks to protect, in part, through confidentiality agreements with employees,
consultants and other parties. There can be no assurance, however, that these
agreements will not be breached, that the Company would have adequate remedies
for such breach, or that the Company's trade secrets will not otherwise become
known to or independently developed by competitors. See "Business --
Intellectual Property."

LACK OF PMA APPROVAL; LIMITED INITIAL REVENUES; COMPLIANCE WITH GOVERNMENT
REGULATIONS

The medical products the Company plans to market are subject to regulation in
the U.S. by the FDA. The process of complying with regulations with respect to
new products can be costly and time-consuming. The first stage of obtaining
formal FDA premarket approval is submission of an application for an IDE. To
obtain an IDE, approval of the investigational plan for the applicable system is
required from the institutional review board within each participating medical
institution as well as from the FDA.

The Company's ICD and catheter ablation products are also subject to a lengthy
and expensive PMA application approval process with the FDA. Such process
requires the Company to conduct lengthy human clinical trials with respect to
its products. The data collected in such clinical trials (both in and outside
the U.S.) are used to prepare the PMA applications for such products. If such
PMA applications are accepted for filing by the FDA, they will be reviewed
further by the FDA and its Circulatory System Devices Panel. After considering
the panel's recommendation, the FDA will determine whether to approve such PMA
applications. Approval of the Company's applications for PMAs for the SENTINEL
ICDs and its catheter ablation systems will depend on a wide variety of factors,
many of which are outside the Company's control. Approval will also require an
inspection by the FDA to determine whether the Company's operations conform with
the FDA's current Good Manufacturing Practices. There can be no assurance that
the Company will be successful in obtaining a PMA for its products in a timely
manner, if at all. Delays in obtaining marketing approvals and clearances in the
U.S. could have a material adverse effect on the Company. The Company is also
subject to certain FDA regulations governing manufacturing practices, packaging
and labelling, and failure to comply with these requirements could have a
material adverse effect on the Company.

Until the Company receives PMA approval, the Company will be subject to
FDA-imposed limitations on the number of ICD implants and catheter ablation
procedures that may be performed as well as the number and location of clinical
sites at which implants and procedures may be performed. As the Company
approaches these limitations, it would be required to apply to the FDA for
approval of additional implants and procedures, but there can be no assurance
that such approval will be received on a timely basis, if at all. The Company
would be unable to sell additional ICDs or conduct additional catheter ablation
procedures in the U.S. if it reaches the limits authorized by the FDA. The
timing of both the IDE and PMA review processes is unpredictable and uncertain,
and the failure to obtain the necessary approvals on a timely basis would have a
material adverse effect on the Company. See "Business -- Products."

The Company's products are also subject to regulation in foreign countries by
agencies comparable to the FDA. Although the Company has obtained a CE Mark for
the SENTINEL 2000 that allows the Company to commence marketing of the SENTINEL
2000 in countries that are members of the EU and the European Free Trade
Association, subject to limited regulations in certain countries, there can be
no assurance that the Company will be successful in obtaining CE Mark approval
for any other products, in a timely manner, if at all, which could have a
material adverse effect on the Company. See "Business -- Government Regulation."

OBLIGATIONS UNDER PACESETTER RELATIONSHIP

The Company and Pacesetter are parties to a Preferred Stock, Preferred Stock
Option and Subordinated Debenture Purchase Agreement (the "Purchase Agreement"),
an OEM Marketing and Manufacturing Agreement (the "OEM Agreement") and a License
Agreement (the "License Agreement"). The Purchase Agreement provides that, until
one year after PMA approval of the Company's first ICD (other than the SENTINEL
2000), Pacesetter will have a right of first refusal any time the Company
receives an offer for the purchase, license, lease or transfer of all or a
substantial portion of the Company's assets or business or for the purchase of a
majority interest in the capital stock of the Company. In connection with this
right of first refusal, Pacesetter will have 21 days after notice to determine
whether it will exercise its right by proceeding with the transaction on the
same terms and conditions as are set forth in such offer. This right of first
refusal could have the effect of delaying, deferring or preventing a change in
control of the Company, which could operate to deny shareholders the receipt of
a premium on their Common Stock and could have a depressive effect on the market
price for the Common Stock. See "-- Anti-Takeover Considerations."

Pursuant to the OEM Agreement, if the Company fails to fulfill all product
quantity, quality and specification requirements with respect to the Company's
ICD and laser catheter ablation products, Pacesetter may elect to manufacture
these products and pay the Company a royalty that is substantially less than the
transfer price payment the Company would have received had it manufactured the
products and sold them to Pacesetter. In addition, the Company may not market
and sell products under its own label until it has satisfied all of Pacesetter's
quantity requirements for such products. There can be no assurance that the
Company will be able to fulfill these requirements, and the failure to do so
could have a material adverse effect on the Company. See "Business --
Manufacturing; -- Sales and Marketing."

The License Agreement also grants Pacesetter a conditional right to sublicense
certain of the Company's ICD patents and patent applications in existence at the
time of the License Agreement (and certain continuation applications) to up to
three separate parties, provided that the Company receives the same
cross-licenses from the sublicensee as Pacesetter receives (or, if Pacesetter
also sublicenses 20 or more of its own patents or patent applications, that
Pacesetter uses its best efforts to secure such cross-licenses for the Company).
The Company has been advised that Pacesetter is under a pre-existing obligation,
by virtue of a previous license agreement with a major competitor, to license
certain patent rights that Pacesetter may acquire to such competitor, and the
Company is aware that a dispute has arisen between these parties with respect to
the ability of Pacesetter to receive royalties or negotiate cross-licenses with
such competitor in connection with the ICD patents and patent applications that
are subject to sublicensing under the License Agreement. Because the Company is
not a party to this dispute, the Company has no control over or knowledge of any
potential outcome of this dispute and is not necessarily bound by the outcome of
this dispute. Pacesetter has also recently initiated a lawsuit against CPI
relating to certain pacemaker and ICD patents. Pursuant to its rights under the
License Agreement to assert and enforce rights to the ICD patents and patent
applications of the Company that are subject to sublicensing under the License
Agreement, Pacesetter and the Company have agreed to join the Company as a party
to the CPI lawsuit and to include certain of such ICD patents and patent
applications in the CPI lawsuit. Accordingly, Pacesetter and the Company have
entered into an agreement with respect to the joint defense of the CPI lawsuit
which provides, among other items, for the payment by Pacesetter of the legal
fees, disbursements and expenses for such joint defense. There can be no
assurance that the Company will receive necessary cross-licenses from third
parties in exchange for the grant of sublicenses to the ICD patents and patent
applications that are subject to the License Agreement. See "Business --
Intellectual Property."

NEED FOR MARKET ACCEPTANCE

Market acceptance of the Company's products will depend, in part, on the
therapeutic capabilities and operating features of its products as compared to
competing products, the Company's ability to demonstrate to the medical
community the clinical efficacy of its products and its ability to manufacture
quality products in sufficient quantities. Failure of the Company's products to
gain market acceptance would have a material adverse effect on the Company.
Although the markets for the Company's products are expected to grow, there can
be no assurance that the Company will participate in such growth. See "Business
- -- Background and Markets; -- Competition."

DEPENDENCE ON SENIOR MANAGEMENT AND OTHER KEY PERSONNEL

The Company's success depends largely on its senior management and other key
personnel. Competition for personnel with significant experience in the medical
device industry is intense. Accordingly, the loss of the services of such
individuals or the inability to hire additional key individuals as required
could have a material adverse effect on the Company, including its current and
future product development efforts. The Company has purchased a $2.0 million
key-person life insurance policy on its Chairman, President and Chief Executive
Officer. See "Management."

UNCERTAINTY OF THIRD PARTY REIMBURSEMENT AND HEALTH CARE REFORM

The Company's ability to market its products successfully in the U.S. and
elsewhere will depend in part on the extent to which reimbursement for the cost
of such products and related treatment will be available from government health
administration authorities (such as the Health Care Financing Administration
("HCFA"), which determines Medicare reimbursement levels), private health
insurers, health maintenance organizations and other third-party payors. Payors
are increasingly challenging the need for and prices of medical products and
services. Payors may deny reimbursement for procedures that they deem
experimental or for devices that are used other than for FDA-approved
indications. Currently, HCFA does not allow Medicare reimbursement for certain
kinds of products and related procedures that have not received PMA approval and
for which underlying questions of safety and effectiveness have not been
resolved, and certain private third-party payors have also begun denying such
reimbursement. Although the Company's ICDs and catheter ablation products are
currently being reimbursed by HCFA and third-party payors, there can be no
assurance that HCFA and the third-party payors will continue to reimburse such
products in the future. Even if some products are approved for reimbursement,
some payors may deny coverage until the procedure becomes generally accepted by
the medical profession. The inability of hospitals and other providers to obtain
reimbursement from third-party payors for the Company's products and related
procedures would have a material adverse effect on the Company.

The Company expects that there will be continued pressure on cost-containment
throughout the U.S. health care system. Reforms may include mandated basic
health care benefits, controls on health care spending through limitations on
the growth of private health insurance premiums and Medicare and Medicaid
spending, the creation of large insurance purchasing groups and fundamental
changes to the health care delivery system. The Company anticipates that
Congress and state legislatures will continue to review and assess alternative
health care delivery systems and payment methodologies and public debate of
these issues will likely continue in the future. Due to uncertainties regarding
the ultimate features of reform initiatives and their enactment and
implementation, the Company cannot predict which, if any, of such reform
proposals will be adopted, when such proposals may be adopted or what impact
they may have on the Company. See "Business -- Third Party Reimbursement."

DEPENDENCE ON THIRD PARTY VENDORS

The Company relies on third party vendors for certain of the components used in
the Company's products and for certain contract manufacturing services. A number
of significant components, such as capacitors, batteries, integrated circuits
and lead systems, are purchased from sole source suppliers. For certain
components and manufacturing services, there are relatively few sources of
supply, and establishing additional or replacement suppliers for such components
or services cannot be accomplished quickly. In addition, each supplier and each
component must be qualified with the FDA, and the time required for such
qualification may be lengthy. Although the Company tries to maintain sufficient
quantities of inventory of such components to minimize production delays or
interruptions, there can be no assurance that the Company will find suitable
alternatives at reasonable prices, if at all, or that any such alternatives will
remain available to the Company. The Company's inability to obtain acceptable
components in a timely manner or find and maintain suitable replacement
suppliers of components or manufacturing services would have a material adverse
effect on the Company, including its ability to manufacture its products. See
"Business -- Manufacturing."

LIMITED MANUFACTURING AND MARKETING EXPERIENCE

To date, the Company's products have been manufactured in limited quantities for
clinical testing purposes and have not been manufactured on a commercial scale.
As a result, there can be no assurance that the Company will not encounter
difficulties in scaling up its manufacturing capabilities, including problems
involving production yields, quality control, component supply and shortages of
qualified manufacturing personnel. Any such difficulties could also result in
the inability of the Company to satisfy Pacesetter's product requirements, which
could result in a royalty from Pacesetter that is significantly lower than the
transfer price payment the Company would have otherwise received. Any
significant manufacturing difficulties could have a material adverse effect on
the Company.

Management of the Company has limited experience in marketing the Company's ICD
and catheter ablation products, sales of which to date have consisted of limited
quantities for use in clinical trials. There can be no assurance that the
Company will be able to recruit and retain the necessary sales managers, direct
salespersons or distributors as needed or that the Company's efforts to scale up
its marketing capabilities will be successful. See "Business -- Sales and
Marketing."

POSSIBLE OBSOLESCENCE DUE TO TECHNOLOGICAL CHANGE

The medical device industry is subject to rapid technological innovation and,
consequently, the life cycle of a particular product tends to be relatively
short. The Company is engaged in a field characterized by extensive research and
development efforts. There can be no assurance that alternative treatments or
other discoveries and developments with respect to ICDs or catheter ablation
systems will not render the Company's products obsolete. Furthermore, the
greater financial and other resources of many of the Company's competitors may
permit such competitors to respond more rapidly than the Company to
technological advances. See "Business -- Competition."

NEED FOR ADDITIONAL FINANCING

The Company may need additional financing following completion of this offering
depending on a number of factors, including: progress with clinical trials; time
and costs involved in obtaining regulatory approvals; costs involved in filing,
prosecuting and enforcing patents or defending against patent infringement
claims; competing technological and market developments; costs of manufacturing
and marketing scale-up; and potential acquisitions. To the extent that
additional financing is needed, however, there can be no assurance that such
additional financing would be available on acceptable terms, if at all, and the
failure to obtain any such additional financing would have a material adverse
effect on the Company. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations."

DILUTION

Purchasers of the shares of Common Stock offered hereby will experience an
immediate dilution in net tangible book value. See "Dilution."

IMPACT OF SHARES ELIGIBLE FOR FUTURE SALE

Upon completion of this offering, based on the number of outstanding shares of
Common Stock as of April 30, 1996, the Company will have approximately 28.4
million shares of Common Stock outstanding (29.0 million shares if the
Underwriters' over-allotment option is exercised in full), assuming no exercise
of outstanding options or warrants and no conversion of an outstanding
convertible debenture or shares of Series A Preferred Stock. Substantially all
of such shares are eligible for immediate resale following completion of this
offering as a result of having been registered for resale under the Securities
Act, pursuant to the provisions of Rule 144 or otherwise. On April 30, 1996, the
Company filed a registration statement registering the resale of 1,269,849
shares of Common Stock issued or issuable upon exercise of certain outstanding
warrants and 1,125,000 shares of Common Stock issuable upon conversion of a
convertible debenture and shares of Series A Preferred Stock held by Pacesetter,
which registration statement was declared effective on June 21, 1996. The
directors and officers of the Company and certain of their affiliates,
beneficially owning as of April 30, 1996, an aggregate of 2,515,886 shares of
Common Stock, have agreed not to sell or otherwise transfer shares of Common
Stock held by them or issuable to them upon exercise or conversion of options,
warrants or other securities (including 324,999 of the shares subject to the
registration statement filed on April 30, 1996) for the period beginning June 1,
1996 and ending 90 days after the effective date of the registration statement
of which this Prospectus is a part (the "Registration Statement"), inclusive
(the "Lock-up Period"). Nevertheless, sales of shares of Common Stock in the
public market during or following expiration of the Lock-up Period could
adversely affect the market price of the Common Stock. See "Underwriting."

POTENTIAL INSUFFICIENCY OF PRODUCT LIABILITY INSURANCE

The testing, manufacturing, marketing and sale of medical devices involves risk
of liability claims and product recalls. As a result, the Company currently
carries product liability insurance covering its products with policy limits of
$5.0 million per occurrence and $5.0 million in the aggregate. It cannot be
predicted, however, whether such insurance is sufficient, or if not, whether the
Company will be able to obtain such insurance as is sufficient, to cover the
risks associated with the Company's business or whether such insurance will be
available at premiums that are commercially reasonable. Lack of sufficient
insurance could expose the Company to substantial damages in connection with
product liability claims or product recalls.

ANTI-TAKEOVER CONSIDERATIONS

The Company's Restated Articles of Incorporation (i) authorize the Company's
Board of Directors, without any action by the shareholders, to establish the
rights and preferences of up to 3,000,000 shares of undesignated preferred stock
(of which 1,225,000 shares remain undesignated as of the date of this
Prospectus) and (ii) provide that the affirmative vote of at least two-thirds of
the voting power of the shares entitled to vote is necessary in connection with
a merger, consolidation or transfer of substantially all of the Company's
assets. The Company also is subject to certain "anti-takeover" provisions of the
Minnesota Business Corporations Act. Moreover, the Purchase Agreement with
Pacesetter provides Pacesetter, for a certain period of time, with a right of
first refusal in connection with any sale of the Company or its assets. In
addition, in April 1996 the Company's Board of Directors adopted a Shareholder
Rights Plan designed to protect the Company and its shareholders from
unsolicited attempts or inequitable offers to acquire the Company. These
measures may, in certain circumstances, deter or discourage takeover attempts
and other changes in control of the Company not approved by the Board. As a
result, the Company's shareholders may lose opportunities to dispose of their
shares at the higher prices generally available in takeover attempts or that may
be available under a merger proposal. In addition, these measures may have the
effect of permitting the Company's current members of the Board to retain their
positions and place them in a better position to resist changes that
shareholders may wish to make if they are dissatisfied with the conduct of the
business of the Company. See "Description of Securities."

LACK OF PROSPECTIVE DIVIDENDS

The Company has not paid dividends on its Common Stock and does not anticipate
paying cash dividends in the foreseeable future. The Company intends to retain
any earnings to finance the development of its business. In addition, as long as
shares of Series A Preferred Stock are outstanding, in the event that dividends
are paid on the Common Stock, holders of such Series A Preferred Stock shall be
entitled to an equivalent dividend on the basis of the number of shares of
Common Stock into which the Series A Preferred Stock is then convertible. There
can be no assurance that the Company will ever pay cash dividends. See "Dividend
Policy."

VOLATILITY OF STOCK PRICE

The market prices for securities of medical device companies have historically
been highly volatile, including the market price of shares of the Company's
Common Stock. Future announcements by the Company or its competitors, including
announcements concerning strategic collaborations, results of clinical testing,
technological innovations or new commercial products, changes in government
regulations, regulatory actions, health care legislation, proprietary rights,
litigation and public concerns as to safety of the Company's or its competitors'
products, as well as period-to-period variances in financial results, could
cause the market price of the Common Stock to fluctuate substantially for
reasons that may be unrelated or disproportionate to the operations of the
Company.

UNSPECIFIED USE OF PROCEEDS

The Company has not allocated to specific uses a portion of the net proceeds of
this offering. These unallocated proceeds will be used for general corporate
purposes, including working capital. Pending such uses, the Company expects that
it will invest such proceeds in short-term, interest-bearing instruments, such
as certificates of deposit and short-term government obligations. Accordingly,
the Company will have broad discretion as to the use of such unallocated
proceeds without any action or approval of the Company's shareholders. See "Use
of Proceeds."

USE OF PROCEEDS

The net proceeds to the Company from the sale of the Shares offered hereby,
after deducting underwriting discounts and commissions and estimated offering
expenses, at a public offering price of $7.00 per share, will be $27,459,500
($31,615,925 if the Underwriters' over-allotment option is exercised in
full).

The Company anticipates that the net proceeds of this offering will be used to
fund expansion of clinical trials (approximately $0.7 million), research and
development (approximately $12.0 million), scale-up and expansion of the
Company's manufacturing activities (approximately $2.5 million), and scale-up
and expansion of the Company's marketing activities (approximately $3.6
million), with the remainder to be used for general corporate purposes,
including working capital. A portion of the net proceeds may also be used to
fund collaborative arrangements or acquisitions of or investments in
complementary businesses, products or technologies, although no such
transactions are currently pending.

The expected use of the net proceeds from this offering is subject to change
based upon factors such as progress of clinical trials, time and costs involved
in obtaining regulatory approvals, costs involved in filing, prosecuting and
enforcing patents and defending against patent infringement claims, competing
technologies and market developments and the cost of manufacturing and marketing
scale-up and expansion. The Company may require additional capital after this
offering depending on a number of factors, and there can be no assurance that
any such additional capital will be available on acceptable terms, if at all.
See "Management's Discussion and Analysis of Financial Condition and Results of
Operations."

Prior to the use of the proceeds of this offering, the Company will invest such
proceeds in short-term, interest-bearing instruments, such as certificates of
deposit and short-term government obligations.

DILUTION

The net tangible book value of the Common Stock of the Company as of April 30,
1996 (based on the unaudited financial statements included herein) was
$21,954,029 or $0.91 per share. "Net tangible book value" per share of Common
Stock represents the total tangible assets of the Company reduced by the total
liabilities and convertible preferred stock of the Company and divided by the
number of shares of Common Stock outstanding. Upon completion of this offering,
after deducting estimated offering expenses and selling commissions and at an
offering price of $7.00 per share, the adjusted net tangible book value of the
Common Stock of the Company as of April 30, 1996 would have been $49,413,529 or
$1.74 per share. The increase in net tangible book value of $0.83 per share
would be due solely to the purchase of the Shares in this offering. Purchasers
in this offering will immediately incur a dilution of $5.26 per share from the
$7.00 offering price of the Shares sold hereby. "Dilution" is determined by
subtracting net tangible book value per share after the offering from the
offering price.

The following table illustrates the resulting dilution in net tangible book
value per share with respect to the Common Stock offered hereby:

Public offering price per share $7.00
Net tangible book value per share at April 30, 1996 $0.91
Increase per share attributable to new investors 0.83
Pro forma net tangible book value per share after offering 1.74
Dilution in net tangible book value per share to new
investors $5.26
</TABLE>

CAPITALIZATION

The following table sets forth the capitalization of the Company at April 30,
1996, and as adjusted to reflect the net proceeds from the sale by the Company
of 4,200,000 shares of Common Stock pursuant to this offering (at a public
offering price of $7.00 per share). See "Management's Discussion and Analysis of
Financial Condition and Results of Operations" and the Company's financial
statements and related notes contained elsewhere in this Prospectus.

<TABLE>
<CAPTION>
APRIL 30, 1996
ACTUAL AS ADJUSTED
<S> <C> <C>

Long-term debt $ 1,500,000 $ 1,500,000
Shareholders' equity:
Convertible preferred stock, series A, $0.01 par
value.
Authorized 1,475,000 shares; issued and outstanding
875,000 shares 3,166,425 3,166,425
Common stock, $0.01 par value.
Authorized 35,000,000 shares; issued and outstanding
24,212,207 shares, 28,412,207 shares as adjusted(1) 242,122 284,122
Additional paid-in capital 60,384,733 87,802,233
Accumulated deficit (37,347,476) (37,347,476)
Total shareholders' equity 26,445,804 53,905,304
Total capitalization $ 27,945,804 $ 55,405,304
</TABLE>

(1) Does not include 3,425,066 shares of Common Stock issuable upon the exercise
of options and warrants outstanding on April 30, 1996.

DIVIDEND POLICY

The Company has not paid dividends on its Common Stock and does not anticipate
paying cash dividends in the foreseeable future. The Company intends to retain
any earnings to finance the development of its business. In addition, as long as
shares of the Company's Series A Preferred Stock are outstanding, in the event
that dividends are declared on the Common Stock of the Company, holders of the
Series A Preferred Stock shall be entitled to receive an equivalent dividend on
the basis of the number of shares of Common Stock into which such holder's
shares of Series A Preferred Stock are then convertible. There can be no
assurance that the Company will ever pay cash dividends.

MARKET PRICE FOR COMMON STOCK

The Common Stock is currently traded on the Nasdaq National Market under the
symbol "ANGN." Prior to October 19, 1995, the Common Stock was traded on the
Nasdaq SmallCap Market. The following table sets forth, for each of the calendar
periods indicated, the range of high and low closing bid quotations per share
until October 19, 1995, as reported by the Nasdaq SmallCap Market, and the range
of high and low closing sale prices of the Common Stock, as reported by the
Nasdaq National Market. These prices do not include adjustments for retail
mark-ups, mark-downs or commissions (and prior to October 19, 1995, represent
inter-dealer quotations and do not necessarily represent actual transactions).

<TABLE>
<CAPTION>
COMMON STOCK
HIGH LOW
<S> <C> <C>

1996:
Third calendar quarter (through July 1,
1996) $ 7.50 $7.50
Second calendar quarter 12.00 7.00
First calendar quarter 11.12 7.62
1995:
Fourth calendar quarter 9.25 5.75
Third calendar quarter 8.38 4.88
Second calendar quarter 4.88 3.38
First calendar quarter 3.75 2.50
1994:
Fourth calendar quarter 3.12 2.38
Third calendar quarter 3.00 2.00
Second calendar quarter 3.00 1.62
First calendar quarter 3.62 2.25
1993:
Fourth calendar quarter 2.88 1.88
Third calendar quarter 3.12 2.00
Second calendar quarter 4.50 3.00
First calendar quarter 4.88 3.62
</TABLE>

For a recent sale price for the Common Stock, see the cover page to this
Prospectus. As of April 30, 1996, the Common Stock was held of record by 560
persons.

SELECTED FINANCIAL DATA

The following selected financial data should be read in conjunction with
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" and the financial statements and notes thereto included elsewhere in
this Prospectus. The statement of operations data for the years ended July 31,
1993, 1994 and 1995 and the balance sheet data at July 31, 1994 and 1995 are
derived from, and are qualified by reference to, the audited financial
statements included elsewhere in this Prospectus and should be read in
conjunction with those financial statements and notes thereto. The statement of
operations data set forth below for the years ended July 31, 1991 and 1992 and
the balance sheet data as of July 31, 1991, 1992 and 1993 are derived from the
audited financial statements of the Company not included herein. The selected
financial data as of and for the nine months ended April 30, 1995 and 1996 have
been derived from unaudited consolidated financial statements of the Company
which, in the opinion of management, include all adjustments, consisting of
normal recurring adjustments, necessary for a fair presentation of such data.
The results of operations for the nine months ended April 30, 1996 are not
necessarily indicative of the results of operations to be expected for the
entire year ending July 31, 1996.

YEAR ENDED JULY 31,
1991 1992 1993 1994 1995
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net sales $ 3,030 $ 77,615 $ 137,982 $ 0 $ 0
Manufacturing expenses(1) 966 169,587 147,755 0 0
Research and development 1,175,986 2,996,845 4,485,818 5,158,738 7,815,391
Sales and marketing(2) 0 0 0 0 0
General and administrative 824,516 1,021,078 1,353,502 1,460,424 1,849,376
Net loss from continuing
operations (1,892,420) (4,054,919) (5,915,558) (7,675,743) (9,643,351)
Gain on sale of discontinued
operations(3) 0 0 3,207,120 0 0
Income (loss) from
discontinued operations 125,817 (106,536) 0 0 0
Net loss $(1,766,603) $(4,161,455) $(2,708,438) $(7,675,743) $(9,643,351)
Net loss per share from
continuing operations $ (0.22) $ (0.41) $ (0.57) $ (0.72) $ (0.58)
Net income (loss) per share
from discontinued
operations 0.01 (0.01) 0.31 0.00 0.00
Net loss per share(4) $ (0.21) $ (0.42) $ (0.26) $ (0.72) $ (0.58)
Weighted average number of
shares outstanding(4) 8,536,984 9,901,592 10,296,812 10,657,311 16,550,915
</TABLE>

WIDE TABLE CONTINUED FROM ABOVE

NINE MONTHS
ENDED APRIL 30,
1995 1996

STATEMENT OF OPERATIONS DATA:
Net sales $ 0 $ 874,959
Manufacturing expenses(1) 0 2,278,242
Research and development 5,268,028 6,717,469
Sales and marketing(2) 12,767 387,634
General and administrative 1,495,868 2,444,543
Net loss from continuing
operations (6,673,157) (10,161,744)
Gain on sale of discontinued
operations(3) 0 0
Income (loss) from
discontinued operations 0 0
Net loss $(6,673,157) $(10,161,744)
Net loss per share from
continuing operations $ (0.41) $ (0.46)
Net income (loss) per share
from discontinued
operations 0.00 0.00
Net loss per share(4) $ (0.41) $ (0.46)
Weighted average number of
shares outstanding(4) 16,291,900 21,953,593

<TABLE>
<CAPTION>
JULY 31, APRIL 30, 1996
1991 1992 1993 1994 1995 ACTUAL AS
ADJUSTED(5)
<S> <C> <C> <C> <C> <C> <C> <C>

BALANCE SHEET DATA:
Cash and cash equivalents $ 1,185,759 $ 927,620 $ 4,842,033 $ 2,127,358 $ 2,367,764 $ 14,789,510 $42,249,010
Short-term investments 0 0 0 0 0 7,328,201 7,328,201
Working capital (deficit) 4,097,908 2,989,426 4,692,607 (1,175,384) 1,669,554 22,953,009 50,412,509
Total assets 4,903,150 5,905,146 7,329,146 4,752,630 5,751,194 30,572,968 58,032,468
Long-term debt, less current
installments 117,604 76,045 1,513,516 1,504,187 1,501,091 1,500,000 1,500,000
Accumulated deficit (2,996,745) (7,158,200) (9,866,638) (17,542,381) (27,185,732) (37,347,476) (37,347,476)
Shareholders' equity
(deficit) 4,544,481 4,404,409 5,207,346 (596,320) 2,980,150 26,445,804 53,905,304
</TABLE>

(1) The amounts reflected in manufacturing expenses for the years ended July 31,
1991, 1992 and 1993 and the nine months ended April 30, 1996 reflect cost of
goods sold for those periods.

(2) Sales and marketing for the years ended July 31, 1991 through 1995 is
included in general and administrative.

(3) Gain on sale of discontinued operations is attributable to the sale of AMP.
See "Management's Discussion and Analysis of Financial Condition and Results
of Operations" and Note 4 of Notes to Financial Statements.

(4) Computed on the basis described for net loss per share in Note 2 of Notes to
Financial Statements.

(5) Adjusted to give effect to the sale of the Shares offered hereby at a per
share offering price of $7.00 and application of the estimated net
proceeds therefrom. See "Use of Proceeds."

MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

The Company's continuing operations consist of the research and development
efforts of its two divisions, the implantable cardioverter defibrillator group
and the catheter ablation group. These divisions are developing medical devices
to treat various types of arrhythmias (irregular heartbeats). The operations
conducted by these divisions were previously conducted by AngeMed, Inc. and
AngeLase, Inc., the Company's two greater-than-90% owned subsidiaries, which
were merged into the Company effective December 20, 1993. See Note 3 of Notes to
Financial Statements. In September 1992, the Company completed the sale of AMP,
an accessory products business, to the B. Braun Cardiovascular Division of
Burron Medical Inc. The sale price consisted of $6.2 million in cash at closing,
plus a royalty of 10% and 5% of AMP product sales in fiscal 1993 and 1994,
respectively. See Note 4 of Notes to Financial Statements. Effective November 1,
1995, the Company also established a European subsidiary, Angeion Europe Ltd.
("Angeion Europe"), to facilitate clinical trials of its ICDs and expand its
European business activities.

The Company has incurred net operating losses from continuing operations in each
year since its inception in 1986. At April 30, 1996, the Company's accumulated
deficit was $37,347,476. Losses have resulted principally from costs incurred in
the research and development of the Company's products. The Company has had
limited revenue since the sale of AMP in September 1992. The Company expects to
incur additional operating losses over the next several years as the Company
continues to fund research and development (including clinical trials) relating
to its ICDs and catheter ablation systems and invests in building its
manufacturing and marketing capabilities. The Company's ability to achieve
profitability is dependent in part on obtaining regulatory approvals for its
products and developing the capacity to manufacture and sell its products
successfully. There can be no assurance that the Company will obtain the
required regulatory approvals on a timely basis, if at all; successfully
develop, commercialize, manufacture and market its products; or achieve
profitability. In addition, the Company's results of operations may fluctuate
significantly from quarter to quarter depending upon a number of factors,
including the availability of third party reimbursement, the timing of
regulatory approvals, progress of product development and clinical trials, the
extent to which the Company's products gain market acceptance, marketing and
manufacturing costs and competition.

Unless otherwise noted, the following discussion of financial condition and
results of operations relates only to the continuing operations of the Company.

RESULTS OF OPERATIONS

NINE MONTHS ENDED APRIL 30, 1995 COMPARED TO NINE MONTHS ENDED APRIL 30, 1996

Net sales increased from $0 in the nine months ended April 30, 1995 to $874,959
in the nine months ended April 30, 1996. The increase was due to the initiation
of sales of defibrillator products to Pacesetter and sales in connection with
European and U.S. clinical trials.

Manufacturing expenses increased from $0 in the nine months ended April 30, 1995
to $2,278,242 in the nine months ended April 30, 1996. The increase was due to
the cost of products sold during the period, as well as start-up costs
associated with the establishment of the Company's manufacturing capabilities.
Manufacturing costs were higher than net sales due to the low volume of net
sales relative to the significant costs incurred as the Company began its
manufacturing activities.

Research and development expenses increased from $5,268,028 in the nine months
ended April 30, 1995 to $6,717,469 in the nine months ended April 30, 1996. This
increase of $1,449,441 was due primarily to an acceleration of research and
development activity (including clinical trials) in connection with the
Company's ICD products. Research and development activity was focused on the
Company's ICD products, which accounted for $5,898,322 of the expenses for the
nine months ended April 30, 1996, while catheter ablation research and
development activities accounted for $819,147 of such expenses. The Company
expects that research and development expenses will continue to increase as the
Company expands human clinical trials, enhances current products and accelerates
the development of new products.

Sales and marketing expenses increased from $12,767 in the nine months ended
April 30, 1995 to $387,634, in the nine months ended April 30, 1996 due
primarily to the hiring of a sales and marketing Vice President and the
initiation of marketing activity.

General and administrative expenses increased from $1,495,868 in the nine months
ended April 30, 1995 to $2,444,543 in the nine months ended April 30, 1996. This
increase of $948,675 was due primarily to an increase in non-cash compensation
expenses resulting from the grant of stock and options and the start-up costs
associated with the establishment of the Company's European subsidiary.

The net loss for the nine months ended April 30, 1995 was $6,673,157, or $0.41
per share, compared to a net loss of $10,161,744, or $0.46 per share, for the
nine months ended April 30, 1996.

YEAR ENDED JULY 31, 1994 COMPARED TO YEAR ENDED JULY 31, 1995

The Company had no sales or manufacturing expenses in either fiscal 1994 or
fiscal 1995.

Research and development expenses increased from $5,158,738 in fiscal 1994 to
$7,815,391 in fiscal 1995. This increase of $2,656,653 was due primarily to an
acceleration of research and development activity on the Company's ICDs.
Research and development activity relating to the Company's ICDs accounted for
$6,772,442 of the expenses for fiscal 1995, while catheter ablation research and
development activities accounted for $1,042,949 of the expenses. During fiscal
1994, there was an additional charge of $1,450,499 representing the purchase of
in-process research and development in connection with the mergers of AngeLase,
Inc. and AngeMed, Inc. into the Company. See Note 3 of Notes to Financial
Statements.

General and administrative expenses increased from $1,460,424 in fiscal 1994 to
$1,849,376 in fiscal 1995. This increase of $388,952 was due primarily to an
increase in payroll and legal expenses.

The net loss for fiscal 1994 was $7,675,743, or $0.72 per share, compared to
a net loss of $9,643,351, or $0.58 per share, for fiscal 1995.

YEAR ENDED JULY 31, 1993 COMPARED TO YEAR ENDED JULY 31, 1994

Net sales and cost of goods sold were $137,982 and $147,755, respectively, in
fiscal 1993. The Company had no sales or cost of goods sold in fiscal 1994. The
decrease was due to the termination of a contract with the Company's only OEM
customer.

Research and development expenses increased from $4,485,818 in fiscal 1993 to
$5,158,738 in fiscal 1994. This increase of $672,920 was due to an acceleration
of research and development activity relating to the Company's ICDs. Research
and development activity relating to the Company's ICDs accounted for $3,981,905
of the expenses for fiscal 1994, while catheter ablation development activities
accounted for $1,176,833 of the expenses. During fiscal 1994, there was an
additional charge of $1,450,499 representing the purchase of in-process research
and development in connection with the mergers of AngeLase, Inc. and AngeMed,
Inc. into the Company. See Note 3 of Notes to Financial Statements.

General and administrative expenses increased from $1,353,502 in fiscal 1993 to
$1,460,424 in fiscal 1994. This increase of $106,922 was due primarily to an
increase in payroll and financing expenses.

The gain on sale of discontinued operations of $3,207,120 in fiscal 1993 was
attributable to the sale of AMP. See Note 4 of Notes to Financial Statements.

The net loss for fiscal 1993 was $2,708,438, or $0.26 per share, compared to a
net loss of $7,675,743, or $0.72 per share for fiscal 1994, which included the
gain on sale of discontinued operations.

LIQUIDITY AND CAPITAL RESOURCES

The Company's liquidity needs have related to, and are expected to continue to
relate to, the research and development activities of its ICD and catheter
ablation divisions, working capital and expenditure requirements of its
manufacturing operations, the acquisition of businesses, products and
technologies and expanded marketing expenditures. The Company has financed its
liquidity needs over the last three fiscal years through the sale of Common
Stock and other equity securities, issuance of long-term debt and notes payable
and the proceeds from the sale of AMP.

Net cash used in operating activities was $5,813,173 in the nine months ended
April 30, 1995 compared to $10,523,988 in the nine months ended April 30, 1996
and was $5,345,958, $5,151,520 and $8,566,889, in fiscal 1993, 1994 and 1995,
respectively. The cash used during these periods was primarily related to
research and development activities of the Company's ICD and catheter ablation
divisions (including clinical trials) and, during the nine months ended April
30, 1996, was also related to the build-up of inventory and the increase in
sales and marketing expenses. These increases were partially offset by increases
in accounts payable and accrued expenses, as the Company began its initial
manufacturing and marketing activities.

The Company continues to expand its patent and trademark portfolio through
internal proprietary development and the acquisition of developed technologies.
The Company's investment in patents and trademarks for the nine months ended
April 30, 1996 totaled $322,023. The Company invested $523,185, $311,167 and
$337,158 in patents and trademarks in fiscal 1993, 1994 and 1995, respectively.
The Company will continue to invest in proprietary technologies and procedures
as warranted. To date, no royalty payments have been made in connection with any
license agreements or other commitments.

The Company's expenditures for fixed assets were $2,543,497 for the nine months
ended April 30, 1996, and were $430,234, $244,254 and $989,351 in fiscal 1993,
1994 and 1995, respectively. Fixed asset expenditures related primarily to
computer equipment, office furniture, production equipment for the ICD division
and research and development equipment. As the Company expands its ICD
production and catheter ablation research capabilities, fixed asset expenditures
are expected to increase.

At April 30, 1996, cash and cash equivalents was $14,789,510 and short-term
investments were $7,328,201. In August 1995, the Company completed a public
offering of 3.4 million shares of Common Stock that resulted in net proceeds of
$20,327,045. In September 1994, the Company completed a public offering of 4.9
million shares of Common Stock and 4.9 million warrants that resulted in net
proceeds of $10,599,122. In March 1996, an additional $11,630,337 in net
proceeds was received from the exercise of these warrants. In fiscal 1993, the
Company completed the sale of AMP and consummated the strategic alliance with
Pacesetter. See Notes 4, 6 and 8 of Notes to Financial Statements.

The Company may need additional financing following completion of this offering
depending on a number of factors, including: progress with clinical trials; time
and costs involved in obtaining regulatory approvals; costs involved in filing,
prosecuting and enforcing patents or defending against patent infringement
claims; competing technological and market developments; costs of manufacturing
and marketing scale-up; and potential acquisitions of businesses, products and
technologies. To the extent that additional financing is needed, however, there
can be no assurance that such additional financing would be available on
acceptable terms, if at all, and the failure to obtain any such additional
financing would have a material adverse effect on the Company.

The Company has net operating loss carryforwards for financial reporting and
federal income tax purposes of approximately $35,000,000, which can be used to
offset taxable income in future years. Future equity offerings combined with
sales of the Company's equity during the preceding years may cause changes in
ownership under Section 382 of the Internal Revenue Code of 1986, which would
limit the use of the Company's net operating loss carryforwards existing as of
the date of the ownership change. Since the Company anticipates continued losses
during the next few years, it is not anticipated that any limitation would have
a material adverse effect on the Company.

For 1997, the Company is required to adopt Statement of Financial Accounting
Standards ("SFAS") No. 121, Accounting for the Impairment of Long-Lived Assets
and for Long-Lived Assets to Be Disposed Of, and SFAS No. 123, Accounting for
Stock-Based Compensation. SFAS No. 121 prescribes accounting and reporting
standards when circumstances indicate that the carrying amount of an asset may
not be recoverable. Initial application of SFAS No. 121 is not expected to
result in recognition of a cumulative effect of a change in accounting principle
by the Company. SFAS No. 123 prescribes accounting and reporting standards for
all stock-based compensation plans. Since the Company intends to elect continued
recognition of certain stock-based compensation using the intrinsic value method
prescribed under Accounting Principles Board Opinion No. 25, Accounting for
Stock Issued to Employees, no material effect on the Company's expense
recognition is expected. However, for transactions with non-employees SFAS No.
123 requires the fair value based method for expense recognition. Currently, the
Company is unable to estimate the impact that will result from this method of
computing expense.

BUSINESS

GENERAL

Angeion Corporation designs, develops and manufactures products that treat
irregular heartbeats (arrhythmias). The Company is developing the SENTINEL
series of implantable cardioverter defibrillators ("ICDs"), which it believes
are among the smallest and most technologically advanced ICDs in clinical trials
or market approved today. ICDs are designed to treat abnormally rapid heartbeats
in the ventricular (or lower) chambers of the heart, a condition known as
ventricular tachycardia ("VT"), and a severe form of VT known as ventricular
fibrillation ("VF"), which if not terminated will lead to sudden cardiac death
("SCD"). ICDs are electronic devices that are implanted within the body and are
connected to the heart with defibrillator leads. These devices monitor the
patient's heartbeat and, in the event of VT or VF, deliver an electrical shock
to return the heartbeat to normal rhythm. Following receipt of an
Investigational Device Exemption ("IDE") from the U.S. Food and Drug
Administration ("FDA"), the Company commenced U.S. clinical trials of its first
SENTINEL model, the SENTINEL 2000, in March 1996. In April 1996, the Company
received CE Mark approval to market the SENTINEL 2000 in the European Union
("EU"). Based on its clinical trial progress to date, the Company plans to
submit its application for Pre-Market Approval ("PMA") for the SENTINEL 2000 and
the SENTINEL 2010 series to the FDA in the first half of calendar 1997.

BACKGROUND AND MARKETS

Arrhythmias (abnormal rhythms of the heart muscle) arise from numerous causes,
including congenital defects, tissue damage due to previous heart attacks or
atherosclerosis and certain other heart diseases. Arrhythmias originate in
either the atria (upper two chambers of the heart) where they are generally not
life-threatening, or the ventricles (the lower two chambers of the heart), where
they can significantly interfere with the pumping of oxygenated blood and can
therefore be life-threatening. VT occurs when the ventricles beat at an
abnormally rapid rate, depriving the ventricles of sufficient time to fill with
blood prior to each contraction and therefore reducing the amount of blood
pumped out of the heart. As a result, tissues and organs are deprived of the
oxygen carried by the blood, causing dizziness, unconsciousness, cardiac arrest
and possibly death.

Episodes of VT occur unpredictably and tend to become more serious over time. VT
can progress to the most serious type of cardiac arrhythmia, VF. In VF, the
heart's normal electrical impulses become disorganized and erratic. Unlike VT,
where the heart continues to contract in an organized fashion though at an
abnormally high rate, in VF the heart ceases to pump blood through the body. If
VF is not terminated quickly, the individual will experience an SCD episode
resulting in unconsciousness due to the heart's failure to pump oxygenated blood
to the body's tissues and organs. Without prompt medical intervention, the
individual typically will die.

Industry analysts estimate that in excess of 1.0 million people in the U.S. have
some form of VT and that more than 400,000 people in the U.S. die from SCD
episodes each year. It is estimated that approximately 60,000 to 70,000 people
survive SCD episodes each year, and approximately 100,000 to 120,000 people are
diagnosed each year with sustained chronic VT in the U.S. Individuals with
sustained chronic VT are considered to have a very high risk of experiencing an
SCD episode. Current treatments for SCD survivors and sustained chronic VT
patients consist primarily of medication, ICDs and open heart surgery.

IMPLANTABLE CARDIOVERTER DEFIBRILLATORS

One of the most effective treatments for individuals at risk of experiencing VT
or VF is an ICD. An ICD is an electronic device that is implanted in the patient
and is connected to the heart with defibrillator leads. The ICD is designed to
monitor the patient's heartbeat and, in the event of VT or VF, to deliver
electric pulses or shocks that return the heartbeat to normal rhythm. Early ICD
devices were larger, requiring more invasive implantation and longer hospital
stays; delivered primarily high-energy shocks that were painful to the patient
and provided more energy than needed to treat the VT or VF; and had short life
spans, requiring replacement every two or three years.

The limitations of these early devices led to the development of more
sophisticated ICDs which are currently on the market and which are characterized
by: (i) reduced size and weight allowing for pectoral implant capability; (ii) a
biphasic waveform (an electrical shock of alternating polarity); (iii) greater
longevity; (iv) transvenous lead systems (allows implantation of the lead
through a vein so that open chest surgery is not required); (v) electrogram
storage capability (storage of intercardiac EKG); (vi) tiered therapy
(electrical shocks of varying intensity depending on the type and severity of
the arrhythmia); (vii) use of the ICD housing as an electrode; and (viii)
programmability (allows the physician to customize therapy to the patient's
condition both before and, more importantly, after implant).

These market estimates may be revised upward based upon the results of a recent
study known as the Multicenter Automatic Defibrillator Implantation Trial (the
"MADIT Study"). This five-year study evaluated the outcomes of high risk,
post-heart attack patients who were treated with drugs compared with those
post-heart attack patients implanted with an ICD. The MADIT study indicated that
patients implanted with an ICD had 54% fewer deaths than those who underwent
conventional drug therapies. The principal clinical investigator for the MADIT
Study estimates that an additional 80,000 people per year could benefit from an
ICD. This potential market size increase, however, may develop slowly until
referral patterns from cardiologists to electrophysiologists become more
established and may not be realized unless Medicare begins reimbursing for some
or all of the costs of a prophylactic implant of an ICD.

Recent developments in automated external defibrillators have the potential to
increase the number of first responders with the capability to treat victims of
SCD. Because SCD causes more than 400,000 deaths annually in the U.S., any
increase in the survival rate of such victims may increase the potential market
for ICDs. Although the market for the Company's ICD products is expected to
grow, there can be no assurance that the Company will participate in such
growth.

INTERVENTIONAL TECHNOLOGIES

Catheter ablation is an emerging therapeutic procedure that, in many cases,
offers the curative benefit of surgery but has the advantages of being a
minimally invasive procedure that exposes the patient to a lower risk of
complications or death, reduces hospitalization and is much less expensive than
open chest surgery. In catheter ablation procedures, an electrophysiological
mapping catheter is guided through an artery or vein into the patient's heart
and to the site of the arrhythmogenic tissue (oxygen deprived heart tissue and
areas of scar tissue resulting from sustained VT which conduct electrical
impulses more slowly than normal tissue and increase the risk of arrhythmia).
The mapping catheter identifies the specific site(s) of electrical malfunction.
A catheter attached to an energy source is then used to transmit energy from an
external source into the arrhythmogenic tissue in an amount sufficient to
thermally damage the tissue. When the ablated tissue is replaced with scar
tissue, the pathway generating the conflicting electrical impulse is eliminated
and the normal conduction of electrical activity is restored.

The potential growth of the catheter ablation market depends upon the condition
to be treated. The use of catheters utilizing RF energy for the treatment of SVT
is growing because atrial ablation sites are easily accessible using current
catheter technology and the RF energy is able to penetrate the thinner tissue of
the atria. The Company believes a more significant market potential for laser
catheter ablation devices, however, is in the treatment of VT using laser
catheter ablation. Although the ventricular wall is too thick to be fully
penetrated by RF energy, ventricular arrhythmias, such as VT, may potentially be
treatable with the application of laser energy. The market for VT laser catheter
ablation is supported by the same patient population for whom drug therapy is
not an acceptable treatment regimen. The following factors are driving the
growth of the overall catheter ablation market: (i) catheter ablation offers a
potential cure for certain forms of arrhythmia rather than simply managing its
symptoms; (ii) catheter ablation is a cost-effective, minimally invasive
procedure; and (iii) advancements in electrophysiology mapping technology, known
as "global mapping," are expected to allow more effective identification of the
source of the arrhythmia. Although the market for the Company's ablation
products is expected to grow, there can be no assurance that the Company will
participate in such growth.

STRATEGY

INNOVATIVE TECHNOLOGIES

The Company's research and development efforts have led to the introduction of
numerous technological innovations for ICDs, including reduced size and weight,
the use of dual batteries and proprietary design features to increase longevity
and certain features providing for greater flexibility in treatment options. The
Company has also made significant technological breakthroughs in its catheter
ablation products. The Company's RF catheter ablation system's porous metal tip,
which provides the ability to perfuse small amounts of water through the metal
electrode tip, minimizes blood coagulation during ablation, allowing the
delivery of larger amounts of power and energy to the cardiac tissue. The
Company believes its laser catheter ablation system is the first catheter
ablation system specifically designed for the treatment of VT. See "--
Products."

EXPERIENCED MANAGEMENT, RESEARCH, ENGINEERING AND MEDICAL PERSONNEL

The Company has assembled a management, research and scientific team with
considerable experience and expertise in the medical device industry. The
Company's personnel and medical advisors have substantial experience in
performing research, developing products, conducting clinical trials, obtaining
regulatory approvals, manufacturing and marketing ICDs and other medical
devices. In addition, the Company has developed relationships and works closely
with leading medical researchers worldwide. See "Management."

STRONG PATENT PORTFOLIO

The Company has assembled what it believes to be a strong patent portfolio
for both its ICD products and its catheter ablation products. As of May 15,
1996, the Company had 63 U.S. issued patents, 16 U.S. patents which have been
allowed but have not yet issued, 36 U.S. patent applications pending, 27
foreign patent applications pending, and additional U.S. patent applications
in preparation. See "-- Intellectual Property."

PACESETTER STRATEGIC ALLIANCE

In addition to establishing its own direct and indirect sales and marketing
channels, the Company has a strategic alliance with Pacesetter, which has one of
the largest cardiovascular distribution networks in the world. This alliance
offers the Company timely access to the worldwide market and provides greater
name recognition and resources. See "-- Sales and Marketing; -- Intellectual
Property."

PRODUCTS

The Company's competitive product strategy is to maintain a broad product
pipeline driven by innovative technologies. The medical device industry,
particularly the ICD portion, is characterized by significant investment in new
technologies. In addition to research in cardiac electrophysiology, the Company
intends to invest significant resources in concurrent new product development
programs. For all products, there can be no assurance that the Company will be
able to meet its development schedules.

IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

The Company believes its ICDs offer certain benefits over competitors' ICDs
currently in clinical trials or market-approved, including reduced size and
weight, increased longevity and greater flexibility in treatment options. The
table below sets forth the Company's ICD products currently under development,
in clinical trials or market-approved:

<TABLE>
<CAPTION>
STATUS
MODEL SIZE/WT. LONGEVITY(1) CURRENT KEY FEATURE OBJECTIVES U.S. EUROPE
<S> <C> <C> <C> <C> <C>

2000 60cc/110gm 7 yrs. * Small size and weight IDE; CE Mark;
* Extended longevity Clinical trials Market-approved
* Optimized biphasic waveform
* Dual battery system
* HOT CAN electrode system
2010 Series
2010 60cc/110gm 7 yrs. * Electrogram storage Pre-clinical Clinical trials
2011 58cc/108gm * Extended programmability
2012 61cc/110gm * Coupled shock fibrillation

2020 Series TBA(2) TBA(2) TBA(2) In development

2030 Series TBD(3) TBD(3) TBD(3) Planning stage

2100 Series TBA(2) TBA(2) * Smaller size and weight In development
* Advanced waveform
* Pulse pretreatment
* Advanced anti-tachy pacing
* Dual chamber pacing
* Atrial therapy

</TABLE>

(1) Based on one shock per quarter and 25% pacing.

(2) To be announced in the future.

(3) To be determined and announced in the future.

SENTINEL 2000. The SENTINEL 2000 system consists of the SENTINEL model 2000 ICD,
the ANGEFLEX transvenous defibrillation lead system that connects the ICD to the
patient's heart, a specialized lap top computer programmer connected to a
programming wand (SMART WAND) and an external defibrillation test system.

The SENTINEL 2000 ICD is characterized by small size (60cc) and weight (110gm),
which allows for universal pectoral implantation. Pectoral implantation in
combination with transvenous leads eliminates the need for abdominal surgery and
thoracotomy (open chest surgery). Pectoral implantation reduces patient trauma,
recovery time and hospitalization costs and increases physician and patient
acceptance. Additionally, this product offers extended longevity through the use
of a dual battery system and other product design features. The SENTINEL 2000
also utilizes the Company's proprietary SMALL CAP TUNED biphasic waveform,
demonstrated in clinical trials to lower defibrillation thresholds. The SENTINEL
2000 features a programmable HOT CAN electrode system, which uses the SENTINEL
2000 housing as an electrode that can be programmed on and off, and programmable
shock configuration to add implant flexibility and further reduce defibrillation
thresholds.

In January 1995, the first fully functional model of the SENTINEL 2000 was
successfully implanted in human patients as part of a limited clinical trial in
Bonn, Germany. Follow-up evaluations of these initial patients have confirmed
that the SENTINEL 2000 is performing as anticipated. Additional implants have
taken place in the United Kingdom and Italy. In April 1996, the Company received
CE Mark approval for the SENTINEL 2000. The CE Mark is a worldwide standard
recognizing safety and quality assurance. This approval allows the Company to
begin marketing its SENTINEL 2000 model in all EU countries, subject to limited
regulations in certain countries. The Company is in the process of building
inventory for commercial introduction of the SENTINEL 2000 in the EU.

In March 1996, the Company initiated U.S. clinical trials of the SENTINEL 2000
following IDE approval. This IDE allows the Company to perform up to 60 implants
in up to 15 centers nationwide. The Company will apply to supplement its
SENTINEL 2000 IDE to include the SENTINEL 2010 series, discussed below, as part
of its current clinical studies. Based on its clinical trial progress to date,
the Company believes that it will submit its PMA application for the SENTINEL
2000 and the SENTINEL 2010 series to the FDA in the first half of calendar 1997.
See "-- Government Regulation."

SENTINEL 2010 SERIES. The SENTINEL 2010 series consists of the 2010, 2011 and
2012 models and contains all of the features of the SENTINEL 2000 plus 5.5
minutes of electrogram storage capability and enhanced programming flexibility
for the electrophysiologist. These models also have a coupled shock fibrillation
feature, which provides testing convenience for the electrophysiologist. The
difference between the three models in the 2010 series relates to lead connector
configuration. The model 2010, like the model 2000, provides a universal
four-port connector for an additional subcutaneous electrode. The model 2011 is
two cubic centimeters smaller than the model 2010 because of its two port low
profile connector. The model 2012 four-port connector is compatible with
competitors' lead systems for replacement applications without the use of
adapters. In May 1996, the SENTINEL 2010 ICD was introduced into human clinical
evaluation in Europe.

SENTINEL 2020 SERIES AND SENTINEL 2030 SERIES. The SENTINEL 2020 series and 2030
series are under development to provide enhanced patient therapy and are
expected to represent product line extensions of the SENTINEL 2000 and SENTINEL
2010 series. Both series of products are scheduled to begin human implants in
calendar 1997.

2100 SERIES. The Company's 2100 series ICDs will be a new generation of ICDs,
designed to offer significant therapeutic enhancements and flexibility over the
prior SENTINEL series ICDs. The Company expects that the 2100 series will have
all the features of the prior SENTINEL series ICDs, plus the following
additional features: (i) smaller size and weight; (ii) advanced lower
defibrillation energy waveform; (iii) pulse pretreatment therapy; (iv) advanced
anti-tachyarrhythmia pacing; (v) dual chamber pacing and sensing; and (vi)
atrial therapy.

LEAD SYSTEMS. The Company has developed a transvenous lead system, the ANGEFLEX
model 4020 series, which is available in four lengths. This lead system has been
approved for commercial sale in Europe and approved for use as part of the U.S.
clinical trials.

The Company is currently testing an alternate OEM transvenous lead system for
use with the SENTINEL series. This lead system is intended to provide single
pass lead defibrillation, pacing and sensing for physicians preferring this
configuration. The Company anticipates filing for IDE approval for this product
by early calendar 1997. Concurrently, the Company is developing its own single
pass transvenous lead system, the ANGEPASS series, that will include pacing,
sensing and defibrillation functions. This lead system is intended to
incorporate the technology of the ANGEFLEX series and will offer smaller size
and flexibility in a single pass configuration. Initial development and testing
of this lead system has commenced and pre-clinical trials are expected to begin
in the first half of calendar 1997.

CATHETER ABLATION SYSTEMS. The Company's objective in the area of ablative
arrhythmia management is to develop a broad product base to serve the needs of
the electrophysiologist. The Company's focus is directed both at atrial
arrhythmias (SVT, atrial fibrillation and atrial flutter) and ventricular
arrhythmias (VT and VF). The Company is developing four catheter-based systems
for non-surgical percutaneous elimination of various forms of cardiac
arrhythmias: a cooled tip RF ablation catheter; a cooled RF linear ablation
catheter; a cooled laser ablation catheter; and a visual ablation catheter. The
Company is also developing catheter accessory products that include a series of
open lumen steerable guide/mapping catheters that can be used in conjunction
with both its RF and laser catheter ablation systems.

COOLED TIP RF ABLATION CATHETER SYSTEM. The Company's cooled tip RF ablation
catheter system consists of the Company's proprietary single use, disposable
catheter coupled to a standard RF generator and infusion pump. Additional
support devices are supplied by the hospital. The Company believes that its RF
catheter offers many features not offered by RF catheters currently in clinical
trials or market-approved. The effectiveness of catheters that are currently in
clinical trials or market-approved is somewhat limited by blood coagulation on
overheated catheter electrodes, which requires removal, cleaning and reinsertion
of the catheter for continued use during the procedure. To address this problem,
the Company's RF catheter utilizes a proprietary porous metal electrode through
which saline is perfused during the ablation procedure. The saline irrigation
fluid both insulates the electrode from blood contact and cools the electrode
tip, thereby minimizing coagulum formation on the electrode while maximizing
lesion size.

The Company has completed preclinical studies with respect to the RF catheter
ablation system at Enders Pediatric Research Center in Boston. These studies
demonstrated the ability of the cooled tip RF catheter to produce larger lesions
in the atrium and ventricle without coagulum formation. In February 1996, the
Company received IDE approval to commence a feasibility study in human patients.
This IDE allows the Company to perform 20 procedures at four centers nationwide
for the treatment of SVT. The Company is currently investigating several
clinical sites and anticipates the commencement of clinical trials in the second
half of calendar 1996.

COOLED RF LINEAR ABLATION CATHETER SYSTEM. The Company's cooled RF linear
ablation catheter is an extension of its cooled tip RF catheter ablation system.
The RF linear ablation catheter, currently under development, is intended for
use in atrial flutter and atrial fibrillation, where linear lesions are
considered a more effective therapy. Competitors' catheters use a series of ring
electrodes that are sequentially activated with RF energy. The Company's RF
linear ablation catheter will use a cooled metal electrode with an adjustable
length feature. Using current RF generators, this catheter can form a linear
lesion with one application of energy, thereby reducing procedure time and
enhancing therapeutic effectiveness.

To date, the Company has constructed prototypes and demonstrated in engineering
studies the ability to make narrow linear lesions with the RF linear ablation
catheter. The Company intends to collaborate with a medical research institution
to complete development of this catheter. Based on its progress to date, the
Company anticipates filing an IDE for the treatment of atrial fibrillation with
the RF linear ablation catheter in the first half of calendar 1997.

COOLED LASER ABLATION CATHETER SYSTEM. The Company's cooled laser catheter
ablation system is targeted at the VT market. Laser energy produces full
transmural lesions of the size and depth most likely to achieve consistently
favorable results in the ventricle with minimal trauma. The Company's
proprietary technology uses a two-piece construction consisting of an inner
laser catheter for delivering energy to the tissue and an outer steerable
mapping catheter for identifying the appropriate arrhythmogenic tissue. The
inner catheter consists of a laser fiber housed in a plastic tube that also
contains irrigation channels, electrical wires and temperature instrumentation.
The catheter is coupled to a laser commonly used in urology and surgery. During
delivery of laser light, saline is perfused through the tip to prevent
coagulation of blood and vaporization of tissue. Temperature sensors in the
laser catheter are embedded in the tissue to safely deliver energy to cardiac
tissue.

The Company's laser technology was developed in conjunction with the experience
of Dr. Robert Svenson, a Medical Advisor to the Company, at the Carolinas
Medical Center. Dr. Svenson has treated 60 VT patients in open chest laser
ablation procedures over a six year period with favorable long term results.
Currently, the Company is conducting an IDE feasibility study to demonstrate the
ability of the laser catheter system to eliminate VT through a minimally
invasive percutaneous procedure. The Company's IDE for the feasibility study
provides for the treatment of 15 patients at two centers.

VISUAL ABLATION SYSTEM. The Company is developing a visually assisted laser
ablation system for certain cardiac therapies that may be anatomically guided.
This visually assisted laser ablation technology incorporates much of the
technology from the Company's current laser ablation system. The visual ablation
system technology integrates an imaging fiber bundle and an expandable balloon
into the Company's steerable mapping catheter. Once inside the heart, the
balloon is filled with saline to a diameter of several centimeters. The imaging
fiber is connected to an endoscopic viewing system to show the internal surfaces
of the heart. Once the appropriate anatomical structures are identified, a laser
fiber is positioned within the balloon to deliver energy to the interior surface
of the heart.

To date, the Company has performed several experiments to verify the ability of
this catheter to visualize the interior surfaces of the heart. After the Company
finalizes the design of this product, it will conduct the necessary studies to
file an IDE application with the FDA.

CATHETER ABLATION ACCESSORY PRODUCTS. The Company plans to provide a broad line
of catheter ablation accessory products for the electrophysiologist. These
accessories may include introducers, fixed mapping catheters, steerable
guide/mapping catheters and extension wires. The Company anticipates that some
of these products will be developed as an extension of its ablation technologies
while others will be purchased from other companies on an OEM ("Original
Equipment Manufacturer") basis or otherwise.

The Company has developed a series of open lumen, steerable guide/mapping
catheters that allow point mapping and accurate, flexible positioning of the
ablation catheter at the proper site. This steerable guide/mapping catheter can
be used with both the Company's RF and laser catheter ablation systems. The
steerable guide/mapping catheter has been studied in preclinical trials and has
been approved by the FDA for use in connection with the Company's laser catheter
human clinical trials. Early indications are that this steerable guide/mapping
catheter will allow a physician to position accurately the ablation catheter
within the ventricular chambers of the heart.

FUTURE PRODUCTS. One of the barriers to increased utilization of ablation
therapies is the time required to perform the mapping necessary to identify the
site of the arrhythmogenic tissue. To be as successful as procedures like
angioplasty, ablation procedure times must be reduced to minutes rather than
hours. Such a reduction in procedure time will be possible only with more
sophisticated techniques for measuring electrical patterns in the heart. Current
point mapping systems require the electrophysiologist to manipulate an electrode
catheter inside the heart and then develop a mental image from the electrical
signals. It is anticipated that procedure times will decrease and catheter
placement accuracy will increase if point mapping systems are replaced by
simultaneous mapping from many electrodes (global mapping), whose signals are
computer analyzed and displayed as a three dimensional graph. Such refined
global mapping technology has not yet been fully developed. The Company is
considering many alternatives in the global mapping area, including entering
into a strategic alliance with another company or research institution to
develop a global mapping system, or a direct investment in a technology or
business.

MANUFACTURING

The Company's manufacturing strategy is focused on the extensive use of proven
process vendors and the utilization of key component suppliers, with final
product assembly, testing, inspection and packaging at the Company's facilities.
The use of outside process vendors minimizes facility and equipment investment,
while providing access to resources that provide a high level of technical
ability with minimal production volume constraints. Key process vendors provide
laser welding, electronic assembly, sterilization, and other process
requirements. Component suppliers provide the Company with high quality
materials and the ability to increase production levels.

The Company currently manufactures its products at its U.S. facility in
Minneapolis, Minnesota, where it employs 55 persons dedicated to manufacturing.
The Minneapolis facility recently received ISO 9002 certification, which
certifies the quality management systems in all aspects of its business, with a
primary emphasis on manufacturing. In addition, the Company has contracted with
an ISO 9002 certified manufacturer in Scotland that will be responsible for
final assembly, testing, packaging, sterilization and labeling of its ICDs and
associated external products for the Company's European sales and clinical
trials. The Company's manufacturing facilities are required to meet and adhere
to all applicable requirements of U.S. and international regulatory agencies,
including current Good Manufacturing Practice regulations and Active Implantable
Medical Device Directive ("AIMDD") standards. These facilities are subject to
periodic inspection and surveillance audits by both U.S. and international
regulatory agencies.

The manufacturing process for the Company's products consists primarily of
assembly of purchased components, testing and inspection operations, packaging
and sterilization. Components are purchased according to the Company's
specifications. A number of significant components, such as capacitors,
batteries, integrated circuits and lead systems, are purchased from sole source
suppliers. For certain of these components, there are relatively few sources of
supply, and establishing additional or replacement suppliers for such components
cannot be accomplished quickly. In addition, each supplier and each component
must be qualified with the FDA, and the time required for such qualification may
be lengthy. Although the Company tries to maintain sufficient quantities of
inventory of such components to minimize production delays or interruptions,
there can be no assurance that the Company will find suitable alternatives at
reasonable prices, if at all, or that any such alternatives will remain
available to the Company. The Company's inability to obtain acceptable
components in a timely manner or find and maintain suitable replacement
suppliers would have a material adverse effect on the Company's ability to
manufacture its products.

Pursuant to the OEM Agreement with Pacesetter, if the Company fails to fulfill
all product quantity, quality and specification requirements with respect to the
Company's ICD and laser catheter ablation products, Pacesetter may elect to
manufacture these products and pay the Company a royalty that is substantially
less than the transfer price payment the Company would have received had it
manufactured the products and sold them to Pacesetter. Even if the Company has
fulfilled all product quantity, quality and specification requirements,
Pacesetter may elect to manufacture up to 50% of Pacesetter's aggregate product
requirements but will be required to pay to the Company a payment that equals
the net margin, as determined in the OEM Agreement, on the products had the
Company manufactured the products and sold them to Pacesetter. To date,
Pacesetter has not elected to manufacture any of the Company's products.

SALES AND MARKETING

The Company will directly market and sell its products under its own label
through its own sales force and through independent distributors. Under the OEM
Agreement with Pacesetter, however, such independent distributors may not also
sell ICDs or laser catheter products that are manufactured by other companies.
In addition, the Company may not market and sell products under its own label
until it has satisfied all of Pacesetter's quantity requirements for such
products. The Company has distributors in Italy, the United Kingdom, Belgium,
Austria and Holland, and direct sales representation in Germany. In December
1995, the Company established its United Kingdom subsidiary, Angeion Europe, to
facilitate its clinical trials of the SENTINEL series of ICDs and expand its
European sales and distribution activities.

The Company will also sell its products through Pacesetter under the terms and
conditions of the OEM Agreement. Pursuant to this agreement, Pacesetter was
granted worldwide marketing and distribution rights on a co-exclusive basis with
the Company to the SENTINEL 2000, the SENTINEL 2010 series and all other ICD
products that are commercially marketed within two years of the first commercial
sales of the SENTINEL 2010 model ICD. Pacesetter has similar rights with respect
to laser catheter products that are commercially marketed within two years of
the first commercial sale of a laser catheter product. Pacesetter's co-exclusive
marketing period will continue for at least seven years from the date of the OEM
Agreement (February 1993), and thereafter will be contingent upon certain
defined minimum product purchases by Pacesetter and its affiliates. Pacesetter's
marketing rights will continue on a non-exclusive basis in the event that the
exclusive period terminates. The Company believes that the worldwide marketing
capability of Pacesetter will be of significant value in establishing a
worldwide market presence for the Company's products.

INTELLECTUAL PROPERTY

The Company believes strongly in protecting its intellectual property and
intends to undertake efforts to obtain patents, when available, in connection
with its research and product development programs. As of May 15, 1996, the
Company had 63 U.S. issued patents, 16 U.S. patents which have been allowed but
have not yet issued, relating to its research and development products, 36 U.S.
patent applications pending, 27 foreign patent applications pending, and
additional U.S. patent applications in preparation.

The Company's patented features and technologies with respect to its ICDs
include: (i) its dual battery system; (ii) a more efficient biphasic waveform
that lowers defibrillation energy thresholds; (iii) the HOT CAN electrode
system, which uses the SENTINEL housing as an electrode that can be programmed
on and off; and (iv) an energy delivery system that permits the ICD to increase
shock effectiveness by directing the current more uniformly throughout the
heart. In addition, the Company's RF catheter utilizes a patented porous metal
electrode through which saline is perfused during the ablation procedure, and
the Company's laser catheter utilizes a patented two-piece construction
consisting of an inner laser catheter for delivering energy to the tissue and an
outer steerable mapping catheter for identifying the appropriate arrhythmogenic
tissue. There can be no assurance, however, that any patents held by the Company
will be valid or otherwise of value to the Company or that any patent applied
for will be granted.

The Company conducts an ongoing evaluation of potential infringement of any
proprietary rights of third parties by the products the Company intends to
market. Regardless of the Company's efforts to evaluate the potential
infringement of any proprietary rights of third parties and the Company's policy
of respecting such rights and not knowingly or willfully infringing such rights,
there can be no assurance that allegations of such infringement will not be
made, or that if made such allegations would not be sustained if litigated.
There has been substantial litigation regarding patent and other intellectual
property rights in the medical device industry, particularly in the ICD market.
To date, many patent and intellectual property disputes in the medical device
area have been settled through licensing or similar arrangements. In
contemplation of such an environment, the Company has developed a strategy of
expanding its patent portfolio in those areas where the Company believes
litigation is most likely to develop in the ICD market, and where the Company
has proven expertise, including defibrillation waveforms, electrode systems,
additional therapies, reduced size and increased device lifetime. While no
assurance can be given that the Company's strategy will be effective or that the
Company's patents in these areas will be adjudicated to be valid if challenged,
or otherwise will be of value in potential negotiations with third parties, the
Company continues to pursue patents in those areas which it has identified as
critical to ICD development.

The Company also relies on trade secrets and proprietary technology. The Company
typically requires its key technical employees and consultants to agree in
writing to keep its proprietary information confidential and, within certain
limitations, to assign all inventions relating to the Company's business to the
Company.

The Company acquired the technology for its continuous-wave laser catheter
system from Dr. Jeffrey Isner and Dr. Richard Clark in 1989. Pursuant to the
assignment agreement, the Company agreed to pay Dr. Isner and Dr. Clark a
royalty of 5% on sales of patented products incorporating this technology for
the life of any patent on this technology. Additionally, in exchange for Dr.
Robert Svenson's efforts in connection with the development of the laser
catheter ablation system, the Company has agreed to pay Dr. Svenson and
Carolinas Medical Center a royalty, when certain conditions are met, of 2% and
3%, respectively, on all paid sales of the Company's laser catheter ablation
products.

Pursuant to the License Agreement with Pacesetter, the Company and Pacesetter
have agreed to cross-license certain of their patents and patent applications.
Under this License Agreement, Pacesetter grants the Company certain
non-exclusive rights to certain patents and patent applications relating to
Pacesetter's ICD products as well as to manufacturing improvements made by
Pacesetter with respect to the Company's ICD products. With respect to the
Company's ICD products, the License Agreement divides the Company's patents and
patent applications into two categories: a first category for which the License
Agreement grants certain exclusive rights for a limited exclusive period, and a
second category for which the License Agreement grants certain non-exclusive
rights. The License Agreement also grants certain non-exclusive rights to the
Company's laser catheter patents and patent applications. The License Agreement
also gives Pacesetter the right to enforce the first category of ICD patents and
patent applications during the limited exclusive period. The License Agreement
provides that the Company always has the right to sublicense all of its patents
and patent applications to third parties to avoid or settle a pending patent
infringement lawsuit, provided that during the limited exclusive period the
Company obtains for Pacesetter as part of any such settlement the same rights
and benefits received by the Company with respect to any patents that are
required or useful to Pacesetter in manufacturing and marketing the Company's
products.

The License Agreement also grants Pacesetter a conditional right to sublicense
the first category of ICD patents and patent applications (and certain
continuation applications) to up to three separate parties, provided that the
Company receives the same cross-license from the sublicensee as Pacesetter
receives (or, if Pacesetter also sublicenses 20 or more of its own patents or
patent applications, that Pacesetter uses its best efforts to secure such
cross-license rights for the Company). The Company has been advised that
Pacesetter is under a pre-existing obligation, by virtue of a previous license
agreement with a major competitor, to license or offer to license certain patent
rights that Pacesetter may acquire to such competitor, and the Company is aware
that a dispute has arisen between these parties with respect to the ability of
Pacesetter to receive royalties or negotiate cross-licenses with such competitor
in connection with the first category of ICD patents and patent applications.
Because the Company is not a party to this dispute, the Company has no control
over or knowledge of any potential outcome of this dispute and is not
necessarily bound by the outcome of this dispute. Pacesetter has also recently
initiated a lawsuit against CPI relating to certain pacemaker and ICD patents.
Pursuant to its rights under the License Agreement to assert and enforce rights
to the ICD patents and patent applications of the Company that are subject to
sublicensing under the License Agreement, Pacesetter and the Company have agreed
to join the Company as a party to the CPI lawsuit and to include certain of such
ICD patents and patent applications in the CPI lawsuit. Accordingly, Pacesetter
and the Company have entered into an agreement with respect to the joint defense
of the CPI lawsuit which provides, among other items, for the payment by
Pacesetter of the legal fees, disbursements and expenses for such joint defense.

Because the License Agreement only requires Pacesetter to secure (or, in certain
circumstances, to use its best efforts to secure) for the Company the same
cross-license rights that it receives from third parties in connection with
sublicenses under the License Agreement, there can be no assurance that the
Company will receive necessary cross-licenses from third parties in exchange for
the grant of sublicenses to the first category of ICD patents and patent
applications. These ICD patents and patent applications, however, represent less
than one-half of the Company's current ICD patent portfolio. As a result, even
if the Company does not receive necessary cross-licenses from third parties in
connection with sublicenses under the License Agreement, the Company believes
that the balance of its patent portfolio should be sufficient to enable the
Company to independently negotiate cross-licenses or otherwise settle
intellectual property disputes with competitors with respect to the Company's
products. Any reduction in the number of patents available to the Company in
connection with any such intellectual property disputes, however, could affect
the ability of the Company to ultimately settle any such disputes on reasonable
terms, if at all, which could have a material adverse effect on the Company.

RESEARCH AND DEVELOPMENT

Research and development expenditures for continuing operations were $4,485,818,
$5,158,738 and $7,815,391 in fiscal 1993, 1994 and 1995, respectively. Research
and development expenditures for the nine months ended April 30, 1996 were
$6,717,469. The Company's research and development is primarily directed at the
development of its existing products and the clinical trials relating to such
products. Approximately 66.8%, 77.2% and 86.7% of the Company's research and
development expenditures in fiscal 1993, 1994 and 1995, respectively, were
directly attributable to the SENTINEL ICD products. Approximately 87.8% of the
Company's research and development expenditures in the nine months ended April
30, 1996 were directly attributable to the Company's ICD products. The Company
expects that research and development expenses will continue to increase as the
Company expands human clinical trials and enhances current products while
accelerating the development of potential new products.

COMPETITION

IMPLANTABLE CARDIOVERTER DEFIBRILLATORS

Competition in the ICD market is intense and most of the Company's primary
competitors have substantially greater financial, manufacturing, marketing,
distribution and technical resources than the Company. While antiarrhythmic
drugs and cardiac ablation therapies (like the Company's laser catheter ablation
system) compete in this market, other manufacturers of ICD devices have claimed
a significant share of the market and are believed to be the Company's primary
competitors. Three companies, Medtronic, Inc. ("Medtronic"), CPI, a division of
Guidant Corporation, and Ventritex, Inc. ("Ventritex"), currently have
PMA-approved products in the ICD market and control virtually all of that market
today. In August 1985, the FDA approved CPI's first commercial defibrillator to
be marketed in the U.S. Medtronic was the second company to receive FDA approval
(February 1993) and Ventritex was the third (April 1993).

The Company believes, based upon industry analyses and attendance by management
at industry meetings, that its SENTINEL series of ICDs are among the smallest
and most technologically advanced ICDs currently in clinical trials or
market-approved. Competitors of the Company, however, many of whom have greater
financial and technical resources than the Company, are developing and
conducting human clinical trials of ICDs with certain common features.

CATHETER ABLATION

Although catheter ablation offers a potential cure for, rather than a treatment
of, SVT and VT, catheter ablation technologies must nonetheless compete with
drug therapy, open heart surgery and ICDs. While drug therapy has in the past
experienced limited effectiveness and adverse side effects, new drugs currently
under development may potentially offer improved treatment outcomes. Catheter
ablation does not currently compete, to a significant extent, with ICDs since
catheter ablation is currently used as a treatment for SVT rather than for VT.
As ablation products evolve and demonstrate efficacy in the treatment of VT, the
Company believes that ablation will increasingly compete with the ICD market.

Competition in the current catheter ablation market includes C.R. Bard, Inc.,
Cordis Corporation (a subsidiary of Johnson & Johnson), Boston Scientific
Corporation, Medtronic, EP Technologies, Inc., Cardiac Pathways Corporation,
Electro-Catheter Corp. and St. Jude Medical, Inc. (which purchased Daig
Corporation). These companies are primarily involved in the treatment of SVT
with RF energy-based catheters. Although RF catheters are not currently
considered effective treatments relating to the ventricle, certain companies are
experimenting with the use of RF energy, as well as other forms of energy, in
the ventricle.

THIRD PARTY REIMBURSEMENT

The Company's ability to commercialize its products successfully will depend in
part on the extent to which reimbursement for the cost of such products and
related treatment will be available from government health administration
authorities, such as HCFA, which determines Medicare reimbursement levels,
private health insurers, health maintenance organizations and other third-party
payors. Payors are increasingly challenging the prices of medical products and
services.

In November 1995 the FDA and HCFA entered into an interagency agreement
establishing a process pursuant to which the FDA will place all IDEs that it
approves into one of two categories, Category A or Category B. Category A
devices are considered experimental and for which the "absolute risk" of the
device type has not been established (i.e., initial questions of safety and
effectiveness have not been resolved for the device type) and will not be
eligible for Medicare reimbursement. Category B devices are considered
non-experimental or investigative devices where the incremental risk is the
primary risk in question (i.e., underlying questions of safety and effectiveness
of that device type have been resolved), or it is known that the device type can
be safe and effective because, for example, other manufacturers have obtained
FDA approval for that device type. A Category B device will be eligible for
Medicare reimbursement if it meets all other Medicare coverage requirements. The
SENTINEL 2000 ICD, and the RF and laser catheter ablation systems are Category B
devices and are currently being reimbursed by HCFA and third-party payors.

Even if the Company obtains PMAs for its products, some payors may deny coverage
until the procedures become generally accepted by the medical profession. There
can be no assurance that HCFA and third-party payors will continue to reimburse
any of the Company's products. The inability of hospitals and other providers to
obtain reimbursement from third-party payors for the Company's products would
have a material adverse effect on the Company. The Company expects that there
will be continued pressure on cost-containment throughout the United States
health care system. This pressure could adversely affect the prices of the
Company's products.

GOVERNMENT REGULATION

The Company's products are all classified as medical devices by the Food, Drug
and Cosmetic Act (the "FDC Act"), and as such, are subject to regulation and
supervision by the FDA, and to regulation by foreign governmental authorities.
These medical devices are also subject to ongoing controls and regulations under
the FDC Act, including registration by the manufacturer, compliance with
established manufacturing practices, device tracking, record-keeping,
advertising, packaging and compliance to standards. Comparable agencies in
certain states and foreign countries also regulate the Company's activities. The
Company's products are subject to recall at any time by the FDA or the Company
if it appears that use of the products could result in unwarranted health risks.

All medical devices intended for human use that are to be marketed in the United
States are placed into one of three regulatory classifications, depending on the
degree of regulatory control to which the device will be subject. Class III
devices, which include life support and life sustaining devices or implants, are
subject to the most stringent controls and require FDA approval prior to
marketing. The Company's ICD products and its catheter ablation systems are
classified as class III devices.

FDA requirements for both the Company's ICD and catheter ablation products
involve obtaining formal FDA premarket approval. The first stage of obtaining
formal FDA premarket approval is submission of an application for an IDE. The
IDE permits clinical evaluations of products on human subjects under controlled
experimental conditions by designated qualified medical institutions. To obtain
an IDE, approval of the investigational plan for the applicable system is
required from the institutional review board within each participating medical
institution as well as from the FDA. The Company has received IDE approval with
respect to its SENTINEL 2000 system and both the RF and laser catheter ablation
systems.

The second stage of formal FDA premarket approval is the PMA application. The
PMA, which is submitted after clinical evaluations are completed under an IDE,
is a comprehensive report of all data and information obtained by the applicant
throughout the product's development and testing. The FDA will grant a PMA if it
finds that the safety and effectiveness of the product have been sufficiently
demonstrated and that the product complies with all applicable regulations and
standards. The FDA may require further clinical evaluation of the product,
terminate the clinical trials, grant premarket approval but restrict the number
of devices distributed, or require additional patient follow-up for an
indefinite period of time. There can be no assurance that the Company will be
successful in obtaining a PMA for any products, which is necessary to market the
Company's products commercially in the U.S. in a timely manner, if at all.
Delays in obtaining marketing approvals and clearances in the U.S. could have a
material adverse effect on the Company.

The Company is required to maintain detailed records relating both to its
maintenance of good manufacturing practices and to defective products and
complaints about its products. The FDA has authority to inspect the Company's
facilities to assure compliance with the FDC Act and regulations thereunder.

Many foreign countries have similar regulatory requirements concerning the
marketing of new medical devices. In January 1995, the AIMDD was fully
implemented in the EU, which is expected to make EU regulatory requirements more
consistent. The time required to obtain approvals required by foreign countries
may be longer or shorter than that required for FDA approval and requirements
for licensing may differ from FDA requirements. The Company is also subject to
certain FDA regulations governing manufacturing practices, packaging and
labelling. Further, the FDA regulates the export of medical devices that have
not been approved or cleared for marketing in the United States. Prior to
commencement of sales outside the U.S., the Company will be required either to
obtain export approval from the FDA or to establish manufacturing capacity
abroad. The Company has received export approval under FDA regulations that
allows shipment of its products to the United Kingdom, and has also contracted
with a manufacturer in Scotland to manufacture its products for use in Europe.
See "-- Manufacturing."

Under the AIMDD, the Company is subject to "prior notice" of intent to conduct
clinical trials in the EU. This process, similar to the FDA IDE process,
requires regulatory documents and test information to be submitted to the
governmental agency of each country in which the Company intends to conduct
clinical trials. In order to commence commercial marketing of its products in
the EU, the Company is required to file for a CE Mark approval. In April 1996,
the Company received CE Mark approval for the SENTINEL 2000 from TUV Product
Service, an organization that certifies the safety of medical device products
and the quality assurance systems put in place by the manufacturer of the
medical device. There can be no assurance, however, that the Company will be
successful in obtaining CE Mark approval for any other products in a timely
manner, if at all, which could have a material adverse effect on the Company.

EMPLOYEES

As of April 30, 1996, the Company had 153 full-time employees, including 17
engaged in administration, 55 in manufacturing, 69 in research and development,
and 12 in regulatory and clinical. There are no unions representing the
Company's employees. The Company believes that its relations with its employees
are good.

FACILITIES

The Company leases approximately 52,000 square feet of office and manufacturing
space in Minneapolis, Minnesota. This space serves as the Company's corporate
headquarters, as well as the research and development and manufacturing
facilities for the ICD and catheter ablation system programs. Rent payments
under the lease are approximately $502,000 per year, including shared real
estate taxes and operating expenses. The primary lease agreement extends through
December 31, 1997. The Company's current space may not be adequate to satisfy
the needs of the Company through the end of the lease. The Company believes,
however, it will be able to secure additional or alternative space at a
commercially reasonable price when needed.

MANAGEMENT

DIRECTORS AND EXECUTIVE OFFICERS

The current directors and executive officers of the Company and their ages, as
of April 30, 1996, are as follows:

<TABLE>
<CAPTION>
NAME AGE TITLE
<S> <C> <C>
Whitney A. McFarlin 55 Chairman of the Board, President and Chief Executive Officer

David L. Christofferson 58 Vice President, Chief Financial Officer and Secretary

Robert S. Garin 53 Vice President of Human Resources

Jennifer M. Marrone 40 Vice President of Regulatory and Clinical Affairs

Gary L. Payment 52 Vice President of Operations

T.V. Rao 53 Vice President of Sales and Marketing

William J. Rissmann 46 Vice President of Engineering

Arnold A. Angeloni 53 Director

Dennis E. Evans 56 Director

Lyle D. Joyce, M.D., Ph.D. 49 Director

Joseph C. Kiser, M.D. 63 Director

Donald D. Maurer 59 Director

Glen Taylor 55 Director
</TABLE>

WHITNEY A. MCFARLIN has been President, Chief Executive Officer and Chairman of
the Board of the Company since September 1993. From June 1990 to September 1993,
Mr. McFarlin was President, Chief Executive Officer, Chairman of the Board and a
founder of Clarus Medical Systems, Inc., a private medical device company
manufacturing products for the orthopedic surgical market ("Clarus"). Prior to
founding Clarus, Mr. McFarlin was President and Chief Executive Officer of
Everest & Jennings International, Ltd., a manufacturer of durable medical
equipment, from June 1985 to May 1990. From December 1977 to May 1985, Mr.
McFarlin was an officer of Medtronic, most recently as Executive Vice President,
where he was responsible for the U.S. pacing business. He serves on the Board of
Directors of several corporations, including Clarus and Zero Corp.

DAVID L. CHRISTOFFERSON joined the Company as Vice President and Chief Financial
Officer in January 1991. Mr. Christofferson was elected as the Company's
Secretary in April 1993, and was elected to the Board of Directors of Angeion
Europe in December 1995. From April 1988 to December 1990, he was a Division
Manager for Excel Office Products, a company he founded in 1986, and which was
acquired in 1988 by General Office Products Company. From 1987 through 1989, he
was Chairman and Chief Financial Officer of Medical Wellness Technologies, Inc.,
a distributor of pain control devices. Prior to 1986, Mr. Christofferson was
employed by Medtronic for over 13 years in various management positions, most
recently as Director of Finance and Administration for the Drug Administration
Devices and Systems Division.

ROBERT S. GARIN joined the Company as Vice President of Human Resources in
January 1995. In December 1995, Mr. Garin was elected to the Board of Directors
of Angeion Europe. Prior to joining the Company, Mr. Garin served as a
management consultant to the Company. From 1985 through 1993, Mr. Garin was a
partner in Garin and Associates, a management and human resources consulting
firm. From 1971 to 1985, Mr. Garin was employed by Medtronic in various
positions including Director of Lead Operations and Director of Human Resources
for Latin American Manufacturing and Sales Operations.

JENNIFER M. MARRONE joined the Company in April 1995 as Vice President of
Regulatory and Clinical Affairs. From November 1993 to April 1995, Ms. Marrone
was Director of Regulatory, Clinical and Quality Assurance/Compliance at Empi,
Inc., a manufacturer of noninvasive biomedical devices. From 1979 to 1993, Ms.
Marrone served in a number of capacities at Medtronic including Manager of
Regulatory Affairs for the bradyarrhythmia and tachyarrhythmia products, where
she prepared and managed Medtronic's PMA applications for its tachyarrhythmia
management devices and transvenous leads. She joined Medtronic in 1979 as Study
Director in Preclinical Research.

GARY L. PAYMENT joined the Company in 1994 as Vice President of Operations. From
1985 to 1994, Mr. Payment held various positions at CPI, most recently as
Director of Manufacturing. Prior to joining CPI, Mr. Payment held several
positions at Medtronic, including Director of Operations, Manufacturing Program
Manager and Director of Quality Assurance.

T.V. RAO joined the Company in August 1995 as Vice President of Sales and
Marketing. In December 1995, Mr. Rao was elected Chairman of the Board of
Directors of Angeion Europe. From 1994 to 1995, Mr. Rao served as Vice President
of Sales and Marketing for Brunswick Biomedical Corporation, a medical device
company. From 1980 to 1994, Mr. Rao served in a number of capacities at
Medtronic, including Director of Product Management for the Tachyarrhythmia
Division, Director of International Marketing for pacing products, Product
Marketing Manager for tachyarrhythmia, and Manufacturing Engineering Manager for
the Energy Technology Division. From 1969 to 1980, Mr. Rao served in various
manufacturing engineering capacities at Onan Corporation.

WILLIAM J. RISSMANN joined the Company in November 1994 as Vice President of
Engineering. Most recently, Mr. Rissmann was Director of Research and
Development in the Advanced Tachy Products division at CPI. From 1990 to
1994, he held several positions at CPI, including Director of Quality Control
and Test Engineering and Manager of Product Planning and Administration. Mr.
Rissmann also has prior experience at St. Jude Medical and Medtronic.

ARNOLD A. ANGELONI has been President of Gateway Alliance, LLC, a financial
consulting firm for start-up ventures and business consolidations, since early
1996. From 1961 to 1995, Mr. Angeloni was employed by Deluxe Corporation, a
provider of check products and services to the financial payments industry, in
various administrative, marketing, and operations positions, most recently as
Senior Vice President and President of the Business Systems Division. Mr.
Angeloni has been a director of the Company since 1990.

DENNIS E. EVANS has been President and Chief Executive Officer of Hanrow
Financial Group Ltd., a merchant banking partnership, since February 1989. He
also serves on the Board of Directors of Minnesota Power & Light Co. and
Astrocom Corporation. Mr. Evans has been a director of the Company since
1990.

LYLE D. JOYCE, M.D., PH.D. has been a cardiothoracic surgeon with the
Minneapolis Heart Institute for more than five years, and is currently the
President of Minnesota Thoracic Group, P.A. Dr. Joyce has been a director of
the Company since 1988.

JOSEPH C. KISER, M.D. is a cardiothoracic surgeon (retired) and a founder of
The Minneapolis Heart Institute and The Minneapolis Heart Institute
Foundation. Dr. Kiser is also a founder of the Minnesota Thoracic Group, P.A.
He practiced cardiothoracic surgery at Abbott Northwestern Hospital as well
as other Minneapolis/St. Paul hospitals for more than 20 years prior to his
retirement in January 1995. Dr. Kiser has been a director of the Company
since 1988.

DONALD D. MAURER was named a director of the Company in January 1996. Mr.
Maurer currently serves as Chairman of the Board and Chief Scientific Officer
of Empi, Inc., a public company. Mr. Maurer founded Empi in 1977, became
Chairman of the Board in 1978, and was named President and Chief Executive
Officer in 1979. Mr. Maurer is also the Chairman of the Board of Medical
Alley, a Minneapolis professional organization representing the interests of
the medical industry.

GLEN TAYLOR has been the Chief Executive Officer and Chairman of the Board of
Taylor Corporation since 1975. Taylor Corporation employs more than 8,000
individuals throughout 60 operating divisions in 15 states, Canada, Europe,
Mexico and Australia. Taylor Corporation's businesses include printing, banking,
direct mail marketing, office supplies and electrical manufacturing. Mr. Taylor
also is the owner of the Minnesota Timberwolves, a National Basketball
Association franchise. From 1980 to 1990, Mr. Taylor served as a Minnesota State
Senator. Mr. Taylor has been a director of the Company since 1992.

MEDICAL ADVISORS

In addition to the Company's Board of Directors and full-time employees, the
Company utilizes a number of Medical Advisors who possess knowledge and
experience in technical and medical areas related to the Company's products. The
Medical Advisors consult with management of the Company concerning the products
being developed and their use by health care professionals. Listed below are the
Company's Medical Advisors:

<TABLE>
<CAPTION>
NAME SERVED SINCE CURRENT POSITIONS
<S> <C> <C>
Robert G. Hauser, M.D. 1994 * Special Adviser to the Chairman and Chief Executive
Officer of the Company.
* President of, and a Cardiologist with, The Minneapolis
Heart Institute (Minneapolis, MN ).

Lyle D. Joyce, M.D., Ph.D. 1988 * President, Minnesota Thoracic Group, P.A.
* Cardiothoracic surgeon with The Minneapolis Heart
Institute (Minneapolis, MN ).

Joseph C. Kiser, M.D. 1988 * Cardiothoracic surgeon (retired) with, and founder
of, The Minneapolis Heart Institute and The
Minneapolis Heart Institute Foundation.

Fabio Leonelli, M.D. 1992 * Assistant Professor of Medicine at the University of
Kentucky.

J. Philip Saul, M.D. 1995 * Associate Professor of Pediatrics and Health Sciences
and Technology at the Harvard Medical School.
* Staff Pediatric Electrophysiologist and Director of
the Cardiology Physiological Research Laboratories
in the Department of Cardiology at Children's
Hospital (Boston, MA).

Robert H. Svenson, M.D. 1991 * Director of Laser and
Applied Technologies Laboratory
at the Carolinas Medical Center (Charlotte, NC).
* Adjunct Professor of Medicine at the University of
North Carolina.

Mark A. Wood, M.D. 1993 * Assistant Professor of Internal Medicine at the
Medical College of Virginia.
* Co-Director of Cardiac Electrophysiology
Laboratories at the Medical College of Virginia and
the McGuire Veterans Administration Medical Center
(Richmond, VA ).
</TABLE>

STAR TEAM

As a supplement to its Medical Advisors, in May 1996 the Company established its
Strategic Tachyarrhythmia Advisory Resource Team (the "STAR Team"). The STAR
Team is made up of leading electrophysiologists, who are recognized as experts
in the use of biomedical devices for the management and treatment of cardiac
arrhythmias. The following is a brief summary of the STAR Team:

DAVID G. BENDITT, M.D. has served as a Medical Advisor to the Company since
1992. Dr. Benditt is a Professor of Medicine and Director of the Cardiac
Electrophysiology Laboratory and Arrhythmia Service at the University of
Minnesota Medical School in Minneapolis, Minnesota. Dr. Benditt is a past
president of the North American Society of Pacing and Electrophysiology
("NASPE") and the American Heart Association -- Minnesota Affiliate, and a
Fellow of the American College of Cardiology. Dr. Benditt serves on the
editorial boards of many peer reviewed journals including the AMERICAN
JOURNAL OF CARDIOLOGY and the JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY.

FRANCIS E. MARCHLINSKI, M.D. is a Professor of Medicine, College of
Pennsylvania, Hahnemann University. Dr. Marchlinski is a member of NASPE and
a Fellow of the American College of Cardiology. Dr. Marchlinski serves on the
editorial boards of many peer reviewed journals including the AMERICAN
JOURNAL OF CARDIOLOGY, PACING AND CLINICAL ELECTROPHYSIOLOGY and the JOURNAL
OF CARDIOVASCULAR ELECTROPHYSIOLOGY.

SANJEEV SAKSENA, M.D. is a Clinical Associate Professor of Medicine and
Pediatrics -- New Jersey Medical School, and a Director of Arrhythmia &
Pacemaker Services, Eastern Heart Institute in Passaic, New Jersey. Dr.
Saksena is the Scientific Chair and President-Elect for NASPE and a Fellow of
the American College of Cardiology. Dr. Saksena serves on the editorial
boards of many peer reviewed journals including the AMERICAN JOURNAL OF
CARDIOLOGY, PACING AND CLINICAL ELECTROPHYSIOLOGY, AMERICAN HEART JOURNAL and
the JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY. Dr. Saksena is also the
Chairman of the Government Relations Committee of NASPE and a member of the
Antiarrhythimics vs. Implantable Defibrillators clinical trial planning and
steering committee of the National Institute of Health.

JOHN F. SWARTZ III, M.D. is the Director, Cardiac Electrophysiology, St.
Francis Medical Center in Tulsa, Oklahoma. Dr. Swartz represents the private
practice customers of the electrophysiology community for the Company. Dr.
Swartz is a member of the American College of Cardiology, and the American
Heart Association. Dr. Swartz is a reviewer for peer reviewed journals
including CIRCULATION, JOURNAL OF AMERICAN COLLEGE OF CARDIOLOGY and AMERICAN
JOURNAL OF CARDIOLOGY.

PATRICK J. TCHOU, M.D. has served as a Medical Advisor to the Company since
1991. Dr. Tchou is the Director of the Cardiac Electrophysiology Laboratory
at the Cleveland Clinic in Cleveland, Ohio, and is a Professor, Department of
Internal Medicine, at The Ohio State University. Dr. Tchou is a member of
NASPE and a Fellow of the American College of Cardiology. Dr. Tchou reviews
manuscripts for such journals as CIRCULATION, JOURNAL OF AMERICAN COLLEGE OF
CARDIOLOGY, PACING AND CARDIAC ELECTROPHYSIOLOGY and the JOURNAL OF
CARDIOVASCULAR ELECTROPHYSIOLOGY.

PRINCIPAL SHAREHOLDERS AND BENEFICIAL
OWNERSHIP OF MANAGEMENT

The following table sets forth information regarding the beneficial ownership of
the Common Stock of the Company as of April 30, 1996, unless otherwise noted by,
(i) Pacesetter, (ii) each director and current executive officer, and (iii) all
executive officers and directors of the Company as a group. To its knowledge,
the Company has no beneficial owner of more than 5% of the outstanding Common
Stock. Unless otherwise noted, all of the shares shown are held by individuals
or entities possessing sole voting and investment power with respect to such
shares.

SHARES OF COMMON STOCK
BENEFICIALLY OWNED(1)
PERCENT OF CLASS
NAME AMOUNT BEFORE OFFERING AFTER OFFERING
<S> <C> <C> <C>
Pacesetter, Inc. 1,125,000 (2) 4.4% 3.8%

Whitney A. McFarlin 358,110(3) 1.5 1.2

David L. Christofferson 145,047(4) * *

Robert S. Garin 10,750(5) * *

Jennifer M. Marrone 10,000(6) * *

Gary L. Payment 28,530(7) * *

T.V. Rao 0 -- --

William J. Rissman 16,250(8) * *

Arnold A. Angeloni 71,902 (9) * *

Dennis E. Evans 744,935 (10) 3.1 2.6

Lyle D. Joyce, M.D., Ph.D. 279,435 (11) 1.2 1.0

Joseph C. Kiser, M.D. 377,836 (12) 1.6 1.3

Donald D. Maurer 0 -- --

Glen Taylor 473,091 (13) 1.9 1.7

All current directors and
executive
officers as a group (13 persons) 2,515,886(14) 10.0 8.5
* Less than 1%.

</TABLE>

(1) Shares not outstanding but deemed beneficially owned by virtue of the right
of a person or member of a group to acquire them within 60 days are treated
as outstanding only when determining the amount and percent owned by such
person or group. As of April 30, 1996, there were 24,212,207 shares of
Common Stock outstanding.

(2) As set forth in a Schedule 13D filed with the Securities and Exchange
Commission on October 11, 1994, this amount consists of (i) 875,000 shares
of Common Stock which may be acquired within 60 days upon the conversion of
Series A Preferred Stock, and (ii) 250,000 shares of Common Stock which may
be acquired within 60 days upon the conversion of a $1,500,000 convertible
subordinated debenture.

(3) Includes 355,156 shares which may be acquired within 60 days upon the
exercise of options.

(4) Includes 144,747 shares which may be acquired within 60 days upon the
exercise of options.

(5) Includes 8,750 shares which may be acquired within 60 days upon the
exercise of options.

(6) Consists of 10,000 shares which may be acquired within 60 days upon the
exercise of options.

(7) Includes 25,000 shares which may be acquired within 60 days upon the
exercise of options.

(8) Consists of 16,250 shares which may be acquired within 60 days upon the
exercise of options.

(9) Includes 45,000 shares which may be acquired within 60 days upon the
exercise of options.

(10) Includes 610,000 shares beneficially owned by Hanrow Financial Group
Ltd. ("Hanrow Financial"). Hanrow Financial is the general partner of
Hanrow Capital Fund and Hanrow Capital Fund III, which own 30,000 and
580,000 shares of Common Stock, respectively. Also includes 41,666
shares which may be acquired within 60 days upon the exercise of
warrants beneficially owned by Hanrow Financial, 41,667 shares which may
be acquired within 60 days upon the exercise of warrants owned by Hanrow
Business Finance, Inc., an affiliate of Hanrow Financial, and 21,000
shares which may be acquired within 60 days upon the exercise of options
held by Mr. Evans. Mr. Evans is the President and Chief Executive
Officer of Hanrow Financial.

(11) Includes 91,000 shares held by the MTA Retirement Plan and Trust FBO Lyle
D. Joyce, 7,500 shares which may be acquired within 60 days upon the
exercise of warrants held by the MTA Retirement Plan and Trust FBO Lyle D.
Joyce, 13,333 shares which may be acquired within 60 days upon the exercise
of warrants and 39,000 shares which may be acquired within 60 days upon the
exercise of options.

(12) Includes 43,567 shares held by the MTA Retirement Plan and Trust FBO Joseph
C. Kiser and 80,833 shares which may be acquired by Dr. Kiser within 60
days upon the exercise of stock options and warrants.

(13) Includes 200,000 shares which may be acquired within 60 days upon the
exercise of warrants and 5,000 shares may be acquired within 60 days upon
the exercise of options.

(14) Includes an aggregate of 1,054,902 shares which may be acquired within 60
days upon the exercise of outstanding options and warrants beneficially
owned by current directors and executive officers.

DESCRIPTION OF SECURITIES

The authorized capital stock of the Company consists of 35,000,000 shares of
Common Stock, par value $.01 per share, 1,475,000 shares of Preferred Stock,
Series A, par value $.01 per share (the "Series A Preferred"), 300,000 shares of
Preferred Stock, Series B, par value $.01 per share (the "Series B Junior
Preferred"), and 1,225,000 shares of Preferred Stock, par value $.01 per share,
the designation, rights and preferences of which have not been determined (the
"Undesignated Preferred").

COMMON STOCK

As of April 30, 1996, there were 24,212,207 shares of Common Stock issued and
outstanding, options outstanding to purchase a total of 2,515,066 shares of
Common Stock, and a debenture convertible into 250,000 shares of Common Stock.
All outstanding shares of Common Stock are fully paid and nonassessable.

The holders of the Common Stock are entitled to one vote for each share held of
record on all matters submitted to a vote of stockholders. Subject to the
preferential rights of the holders of the Undesignated Preferred with respect to
dividends, holders of the Common Stock are entitled to receive ratably such
dividends as may be declared by the Board of Directors out of funds legally
available therefor. Holders of the Common Stock have no preemptive rights and no
right to convert their Common Stock into any other securities.

SERIES A PREFERRED

As of April 30, 1996, there were 875,000 shares of Series A Preferred issued and
outstanding. Series A Preferred, at the option of the holder, may be converted
into Common Stock at the rate of one share of Common Stock for each share of
Series A Preferred, subject to certain antidilution adjustments. The holders of
the Series A Preferred are entitled to vote on any matter submitted to a vote of
the holders of the Common Stock of the Company as if the Series A Preferred had
been converted into Common Stock. All shares of Series A Preferred are entitled
to a liquidation preference in cash equal to $4.00 per share before the payment,
distribution or setting apart for payment or distribution of any amount for the
holders of the Common Stock. In addition, as long as shares of Series A
Preferred are outstanding in the event that dividends are declared on the Common
Stock of the Company, holders of the Series A Preferred shall be entitled to
receive an equivalent dividend on the basis of the number of shares of Common
Stock into which such holder's shares of Series A Preferred are then
convertible.

UNDESIGNATED PREFERRED

Under Minnesota law, no action by the Company's shareholders is necessary, and
only action by the Board of Directors is required, to authorize the issuance of
any of the undesignated shares of Undesignated Preferred. Subject to certain
limitations, the Board of Directors is empowered to establish, and to designate
the name of each class or series of the shares of Undesignated Preferred and to
set the terms of such shares (including terms with respect to redemption,
sinking fund, dividend, liquidation, preemptive, conversion and voting rights
and preferences). The Board of Directors can issue shares of such class or
series to, among other individuals, the holders of another class or series of
Undesignated Preferred or to the holders of the Common Stock. Accordingly, the
Board of Directors without shareholder approval can issue Undesignated Preferred
with voting or conversion rights which could adversely affect the voting power
of the holders of the Common Stock. The Undesignated Preferred may have the
effect of discouraging an attempt, through acquisition of a substantial number
of shares of the Common Stock, to acquire control of the Company with a view to
effecting a merger, sale or exchange of assets or a similar transaction.

WARRANTS

As of April 30, 1996, the Company had outstanding warrants to purchase an
aggregate of 910,000 shares of its Common Stock. The weighted average exercise
price per share is $2.04. Such warrants are exercisable at present and for
periods of up to three years. The Company is not able to determine whether or
when any such warrants will be exercised or what impact, if any, any such
exercise might have on the price of the Common Stock.

CERTAIN ANTI-TAKEOVER PROVISIONS

The Company is governed by the provisions of Sections 302A.671 and 302A.673 of
the Minnesota Business Corporation Act. These anti-takeover provisions could
potentially operate to deny shareholders the receipt of a premium on their
Common Stock and may also have a depressive effect on the market price of the
Company's Common Stock. Section 302A.671 generally provides that the shares of a
corporation acquired in a "control share acquisition" have no voting rights
unless voting rights are approved by the shareholders in a prescribed manner. A
"control share acquisition" is generally defined as an acquisition of beneficial
ownership of shares that would, when added to all other shares beneficially
owned by the acquiring person, entitle the acquiring person to have voting power
of 20% or more in the election of directors. Section 302A.673 prohibits a public
corporation from engaging in a "business combination" with an "interested
shareholder" for a period of four years after the date of the transaction in
which the person became an interested shareholder, unless the business
combination is approved in a prescribed manner. A "business combination"
includes mergers, asset sales and other transactions. An "interested
shareholder" is a person who is the beneficial owner of 10% or more of the
corporation's voting stock. Reference is made to the detailed terms of Sections
302A.671 and 302A.673 of the Minnesota Business Corporation Act.

Furthermore, Section 3.5 of Article III of the Company's Restated Articles of
Incorporation provides that the affirmative vote of the holders of two-thirds of
the voting power of the shares entitled to vote is required for shareholder
approval of a plan of merger, exchange of securities, or transfer of assets, as
described in Section 302A.601 of the Minnesota Business Corporation Act.

SHAREHOLDERS' RIGHTS PLAN

The Company has in effect a Shareholders' Rights Plan (the "Rights Plan"),
pursuant to which each share of Common Stock now outstanding has, and each share
offered hereby or issued prior to a Distribution Date will have, attached to it
one Preferred Stock Purchase Right (a "Right") that entitles the holder thereof
to purchase from the Company one one-thousandth of a share of Series B Junior
Preferred Stock of the Company at a purchase price of $70.00, subject to
adjustment. Separate certificates evidencing Rights will not be issued and the
Rights will not be exercisable until the occurrence of a Distribution Date, as
described below. All Rights expire on April 7, 2006, unless earlier exercised or
redeemed.

A Distribution Date will occur upon the earlier of ten business days after (i) a
public announcement that a person or group (an "Acquiring Person") has acquired
beneficial ownership of 15% or more of the Company's Common Stock, (ii) the
commencement of a tender offer or exchange offer that would result in a person
or group beneficially owning 15% or more of the Common Stock, or (iii) a
majority of the members of the Board who are unaffiliated with an Acquiring
Person or Adverse Person (as defined below) determines that any person or group
is an Adverse Person. Pursuant to the Rights Plan, the Board may make an Adverse
Person determination if it finds that a holder of at least 10% of the Company's
outstanding shares (i) acquired such shares either to cause the Company to
repurchase the shares or to enter into a transaction intended to provide such
person with short-term financial gain under circumstances that are not in the
best long-term interests of the Company's shareholders, or (ii) is causing or is
reasonably likely to cause a material adverse impact on the business or
prospects of the Company.

If a merger of the Company into an Acquiring Person occurs, any person acquires
beneficial ownership of 15% or more of the Company's Common Stock (except
pursuant to an offer for 100% of the shares approved by a majority of the
independent directors of the Company) or certain defined self-dealing events
between the Company and an Acquiring Person occur, each Right automatically
adjusts to permit the holder thereof to purchase that number of shares of Common
Stock which at the time of such transaction would have a market value of two
times the exercise price of the Right. However, Rights are not exercisable
following the occurrence of any of the events set forth above until the Rights
are no longer redeemable by the Company. Notwithstanding any of the foregoing,
all Rights that are, or (under certain circumstances) were, beneficially owned
by any Acquiring Person become null and void. The Company has the option, if the
Rights become exercisable, to exchange one share of Common Stock, or substitute
consideration consisting of cash, securities of the Company or other assets, for
each Right, except the void Rights.

At any time prior to the earlier to occur of (i) a person becoming an Acquiring
Person or (ii) the expiration of the Rights, the Company may redeem the Rights
in whole at a price of $.005 per Right (payable in cash or stock).

Any of the provisions of the Rights Plan may be amended, without the vote of
Rights holders, by the Board of Directors prior to the Distribution Date. After
the Distribution Date, certain limitations apply to the ability of the Board to
amend the Rights Plan.

The Rights Plan may have an anti-takeover effect in that any person or group
acquiring control of the Company without the consent of the Company's Board of
Directors could suffer substantial dilution through operation of the Rights
Plan.

REGISTRATION RIGHTS

Under the terms of various warrant agreements, the Company has granted certain
demand and "piggyback" registration rights covering the possible disposition of
up to 1,269,849 shares issued or issuable upon the exercise of such warrants.
The warrants containing such registration rights are exercisable at present. In
addition, pursuant to the Purchase Agreement, Pacesetter has certain demand and
"piggyback" registration rights covering the possible disposition of up to
1,125,000 shares of Common Stock issuable upon conversion of the Series A
Preferred and a convertible debenture. The Company filed a Registration
Statement on Form S-3 on April 30, 1996 registering the resale of all of the
foregoing 2,394,849 shares, which Registration Statement was declared effective
on June 21, 1996.

UNDERWRITING

The Underwriters named below, acting through their representatives, Raymond
James & Associates, Inc., NatWest Securities Limited and Salomon Brothers Inc
(the "Representatives"), have severally agreed, subject to the terms and
conditions of the Underwriting Agreement, to purchase an aggregate of 4,200,000
shares of Common Stock from the Company at the Price to Public set forth on the
cover page of this Prospectus, less the underwriting discounts and commissions,
in the amounts set forth opposite their respective names below.

<TABLE>
<CAPTION>
NUMBER
UNDERWRITER OF SHARES
<S> <C>

Raymond James & Associates, Inc. 910,000
NatWest Securities Corporation 910,000
Salomon Brothers Inc 910,000
Bear, Stearns & Co. Inc. 85,000
Alex. Brown & Sons Incorporated 85,000
Hambrecht & Quist LLC 85,000
Lazard Freres & Co. LLC 85,000
Lehman Brothers Inc. 85,000
Morgan Stanley & Co. Incorporated 85,000
Nesbitt Burns Securities Inc. 85,000
PaineWebber Incorporated 85,000
Prudential Securities Incorporated 85,000
Robertson, Stephens & Company LLC 85,000
Allen & Company Incorporated 45,000
Cowen & Company 45,000
Dain Bosworth Incorporated 45,000
Furman Selz LLC 45,000
Gerard Klauer Mattison & Co., LLC 45,000
John G. Kinnard & Company,
Incorporated 45,000
Morgan Keegan & Company, Inc. 45,000
Needham & Company, Inc. 45,000
Piper Jaffray Inc. 45,000
The Robinson-Humphrey Company, Inc. 45,000
Wheat First Butcher Singer 45,000
Pennsylvania Merchant Group Ltd 25,000
Southcoast Capital Corp. 25,000
Southwest Securities Inc. 25,000
Vector Securities International, Inc. 25,000
Wedbush Morgan Securities Inc. 25,000
Total 4,200,000
</TABLE>

The nature of the Underwriters' obligations under the Underwriting Agreement is
such that all shares of the Common Stock offered hereby, excluding shares
covered by the over-allotment option granted to the Underwriters, must be
purchased if any are purchased. The Company has been advised by the
Representatives that the Underwriters propose to offer the shares of Common
Stock to the public initially at the Price to Public set forth on the cover page
of this Prospectus, and to certain dealers at such price less a concession not
in excess of $0.235 per share. The Underwriters may allow, and such dealers may
reallow, a concession not in excess of $0.10 per share to other dealers. After
the public offering, the offering price and other selling terms may be changed
by the Representatives.

The Company has granted to the Underwriters an option, exercisable within 30
days of the date of this Prospectus, to purchase up to 630,000 additional shares
of the Common Stock solely to cover over-allotments, if any, at the same price
per share to be paid by the Underwriters for the other shares of Common Stock
offered hereby. If the Underwriters purchase any such additional shares pursuant
to the over-allotment option, each of the Underwriters will be committed to
purchase such additional shares in approximately the same proportion as set
forth in the above table. The Underwriters may purchase such shares only to
cover over-allotments, if any, in connection with the offering made hereby.

The Company and each of its officers and directors and certain of their
affiliates have agreed not to offer, sell, contract to sell, or otherwise
dispose of any shares of Common Stock of the Company, or securities convertible
into or exercisable for shares of Common Stock of the Company, without the prior
consent of Raymond James & Associates, Inc., during the period beginning June 1,
1996 and ending 90 days from the effective date of the Registration Statement,
inclusive. This restriction does not apply to shares of Common Stock issued by
the Company pursuant to the conversion or exercise of stock options, warrants,
convertible preferred stock or convertible debentures outstanding on the
effective date of the Registration Statement.

In connection with this offering, the Underwriters may engage in passive market
making transactions in the Common Stock on the Nasdaq National Market
immediately prior to the commencement of sales in this offering, in accordance
with Rule 10b-6A under the Securities and Exchange Act of 1934, as amended (the
"Exchange Act"). Passive market making consists of displaying bids on the Nasdaq
National Market limited by the bid prices of independent market makers and
purchases limited by such prices. Net purchases by a passive market maker on
each day are limited to a specified percentage of the passive market maker's
average daily trading volume in the Common Stock during a specified prior period
and must be discontinued when such limit is reached. Passive market making may
stabilize the market price of the Common Stock at a level above that which might
otherwise prevail and, if commenced, may be discontinued at any time.

The Company and the Underwriters have agreed to indemnify each other against
certain liabilities, including certain liabilities under the Securities Act.
Such indemnification is limited or unavailable in certain circumstances,
including where legally unavailable.

NatWest Securities Limited, a United Kingdom broker-dealer and a member of the
Securities and Futures Authority Limited, has agreed that, as part of the
distribution of the shares of Common Stock offered hereby and subject to certain
exceptions, it will not offer or sell any shares of Common Stock within the
United States, its territories or possessions or to persons who are citizens
thereof or residents therein. The Underwriting Agreement does not limit the sale
of the shares of Common Stock offered hereby outside the U.S.

NatWest Securities Limited has also represented and agreed that (i) it has not
offered or sold and will not offer or sell any Common Stock to persons in the
United Kingdom prior to admission of the Common Stock to listing in accordance
with Part IV of the Financial Services Act 1986 (the "Act") except to persons
whose ordinary activities involve them in acquiring, managing, holding or
disposing of investments (as principal or agent) for the purpose of their
businesses or otherwise in circumstances which have not resulted and will not
result in an offer to the public in the United Kingdom within the meaning of the
Public Offers of Securities Regulations 1995 or the Act; (ii) it has complied
and will comply with all applicable provisions of the Act with respect to
anything done by it in relation to the Common Stock in, from or otherwise
involving the United Kingdom; and (iii) it has only issued or passed on and will
only issue or pass on, in the United Kingdom any document received by it in
connection with the issue of the Common Stock, other than any document which
consists of or any part of listing particulars, supplementary listing
particulars or any other document or instrument required or permitted to be
published by listing rules under Part IV of the Act, to a person who is of a
kind described in Article 11(3) of the Financial Services Act 1986 (Investment
Advertisements) (Exemptions) Order 1995 or is a person to whom the document may
otherwise be lawfully issued or passed on.

The Company has agreed that, until August 1998, Raymond James & Associates, Inc.
shall have a right of first refusal to serve as lead manager or agent in
connection with any proposed offering of securities by the Company or by any
affiliates thereof, to serve as the investment banker to the Company in
connection with any merger, acquisition or consolidation involving the Company
or any affiliate, and to serve as the investment banker to the Company in
connection with any other transaction with respect to which the Company proposes
to engage an investment banker. If Raymond James & Associates, Inc. agrees to
render its assistance for any such transaction, it shall be for fees and
expenses competitive with those that would likely be charged by comparable
investment banking firms. As of April 30, 1996, Raymond James & Associates, Inc.
owned of record 359,850 shares of Common Stock of the Company. On April 30,
1996, the Company filed a registration statement on Form S-3 registering for
resale all of such shares, which registration statement was declared effective
on June 21, 1996.

LEGAL MATTERS

Certain legal matters with respect to the validity of the shares of Common Stock
offered hereby will be passed upon for the Company by Oppenheimer Wolff &
Donnelly, Minneapolis, Minnesota. Certain legal matters will be passed upon for
the Underwriters by Hale and Dorr, Boston, Massachusetts.

EXPERTS

The financial statements of Angeion Corporation as of July 31, 1994 and 1995,
and for each of the years in the three-year period ended July 31, 1995, included
and incorporated herein and in the registration statement by reference, have
been so included and incorporated herein by reference in reliance upon the
report of KPMG Peat Marwick LLP, independent certified public accountants,
included and incorporated by reference herein, and upon the authority of said
firm as experts in accounting and auditing.

The statements in the Prospectus under the captions "Risk Factors -- Importance
of Intellectual Property Protection" and "Business -- Intellectual Property" and
other references herein to intellectual property-related matters have been
reviewed and approved by Patterson & Keough, P.A., patent counsel to the
Company, as experts on such matters, and are included herein
in reliance upon that review and approval.

AVAILABLE INFORMATION

The Company is subject to the informational requirements of the Exchange Act
and, in accordance therewith, files reports, proxy statements and other
information with the Securities and Exchange Commission (the "Commission"). Such
reports, proxy statements and other information can be inspected and copied at
the Public Reference Section of the Commission at Room 1024, 450 Fifth Street,
N.W., Washington, D.C. 20549, and at the following Regional Offices of the
Commission: New York Regional Office, 7 World Trade Center, 13th Floor, New
York, New York 10048; and Chicago Regional Office, Citicorp Center, Suite 1400,
500 West Madison Street, Chicago, Illinois 60661. Copies of such material can
also be obtained at prescribed rates by writing to the Public Reference Section
of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549.

The Company has filed with the Commission a Registration Statement on Form S-3
under the Securities Act. This Prospectus does not contain all of the
information, exhibits and undertakings set forth in the Registration Statement,
certain portions of which are omitted as permitted by the rules and regulations
of the Commission. Copies of the Registration Statement and the exhibits are on
file with the Commission and may be obtained, upon payment of the fee prescribed
by the Commission, or may be examined, without charge, at the offices of the
Commission set forth above. For further information, reference is made to the
Registration Statement and its exhibits.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The following documents filed with the Commission by the Company (File No.
0-17019) are incorporated into this Prospectus by reference: (a) Annual Report
on Form 10-K for the year ended July 31, 1995; (b) Quarterly Reports on Form
10-Q for the quarters ended October 31, 1995, January 31, 1996 and April 30,
1996; (c) Current Report on Form 8-K, dated October 31, 1995; (d) Current Report
on Form 8-K, dated April 8, 1996, as amended on May 17, 1996; (e) all other
reports filed by the Company pursuant to Sections 13(a) or 15(d) of the Exchange
Act since July 31, 1995; (f) the description of the Company's Common Stock
contained in its Registration Statement on Form 8-A and any amendments or
reports filed for the purpose of updating such description; and (g) the
description of the Company's Series B Junior Preferred Stock and rights to
purchase Series B Junior Preferred Stock contained in its Registration Statement
on Form 8-A and any amendments or reports filed for the purpose of updating such
description.

All documents filed by the Company with the Commission pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Prospectus
and prior to the termination of the offering of the Shares shall be deemed to be
incorporated by reference in this Prospectus and to be a part hereof from the
date of filing of such documents. Any statement incorporated or deemed to be
incorporated herein by reference shall be deemed to be modified or superseded
for purposes of this Prospectus to the extent that a statement contained herein
or in any other subsequently filed document which also is or is deemed to be
incorporated herein by reference modifies or supersedes such statement. Any such
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Prospectus.

The Company will provide without charge to each person to whom a copy of this
Prospectus is delivered, upon written or oral request of such person, a copy of
any or all of the documents referred to above which are incorporated by
reference in this Prospectus, other than exhibits to such documents (unless such
exhibits are specifically incorporated by reference in such documents). Written
requests for such copies should be directed to Angeion Corporation, 3650
Annapolis Lane, Suite 170, Minneapolis, Minnesota 55447-5434, Attention: Chief
Financial Officer; telephone number: (612) 550-9388.

INDEX TO FINANCIAL STATEMENTS

<TABLE>
<CAPTION>
PAGE
<S> <C>
Independent Auditors' Report F-2

Balance Sheets as of July 31, 1994 and 1995 F-3

Statements of Operations for the Years Ended July 31, 1993, 1994 and 1995 F-4

Statements of Shareholders' Equity (Deficit) for the Years Ended July 31, 1993,
1994 and 1995 F-5

Statements of Cash Flows for the Years Ended July 31, 1993, 1994 and 1995 F-6

Notes to Financial Statements F-7

Unaudited Consolidated Balance Sheet as of April 30, 1996 F-12

Unaudited Consolidated Statements of Operations for the Nine Months Ended
April 30, 1995 and 1996 F-13

Unaudited Consolidated Statements of Cash Flows for the Nine Months Ended
April 30, 1995 and 1996 F-14

Notes to Unaudited Consolidated Financial Statements F-15
</TABLE>

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
of Angeion Corporation:

We have audited the accompanying balance sheets of Angeion Corporation as of
July 31, 1994 and 1995, and the related statements of operations, shareholders'
equity (deficit), and cash flows for each of the years in the three-year period
ended July 31, 1995. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Angeion Corporation as of July
31, 1994 and 1995, and the results of its operations and its cash flows for each
of the years in the three-year period ended July 31, 1995, in conformity with
generally accepted accounting principles.

KPMG Peat Marwick LLP

Minneapolis, Minnesota
September 14, 1995

ANGEION CORPORATION
BALANCE SHEETS

<TABLE>
<CAPTION>
JULY 31,
1994 1995
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 2,127,358 $ 2,367,764
Other receivable 38,697 0
Royalty receivable 144,978 0
Inventories 230,211 398,788
Prepaid expenses and other current assets 128,135 172,955
Total current assets 2,669,379 2,939,507
Property and equipment, net 998,876 1,602,774
Patents and trademarks, net 905,875 1,055,229
Other assets 178,500 153,684
Total assets $ 4,752,630 $ 5,751,194
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable $ 415,825 $ 836,301
Accrued payroll, vacation and related costs 337,758 238,599
Notes payable, net of discount of $167,000 2,833,000 0
Current installments of capital lease obligations 9,328 2,599
Other accrued expenses 248,852 192,454
Total current liabilities 3,844,763 1,269,953
Long-term debt 1,500,000 1,500,000
Capital lease obligations, less current installments 4,187 1,091
Total liabilities 5,348,950 2,771,044
Shareholders' equity (deficit):
Convertible preferred stock, series A, $0.01 par
value.
Authorized 1,475,000 shares; issued and outstanding
875,000 shares in 1994 and 1995 3,166,425 3,166,425
Common stock, $0.01 par value.
Authorized 35,000,000 shares; issued and outstanding
11,152,935 shares in 1994 and 17,500,529 shares in
1995 111,529 175,005
Additional paid-in capital 13,668,107 26,824,452
Accumulated deficit (17,542,381) (27,185,732)
Total shareholders' equity (deficit) (596,320) 2,980,150
Commitments (notes 10 and 13)
Total liabilities and shareholders' equity (deficit) $ 4,752,630 $ 5,751,194
</TABLE>

The accompanying notes are an integral part of the financial statements.

ANGEION CORPORATION
STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
YEAR ENDED JULY 31,
1993 1994 1995
<S> <C> <C> <C>
Net sales $ 137,982 $ 0 $ 0
Cost of goods sold 147,755 0 0
Gross margin (9,773) 0 0
Operating expenses:
Research and development 4,485,818 5,158,738 7,815,391
General and administrative 1,353,502 1,460,424 1,849,376
Merger expense for in-process
research and development 0 1,450,499 0
Total operating expenses 5,839,320 8,069,661 9,664,767
Operating loss from continuing operations (5,849,093) (8,069,661) (9,664,767)
Other income (expense):
Royalty income 0 482,853 0
Interest income 115,852 72,250 292,578
Interest expense (76,019) (161,185) (271,162)
Other expense (106,298) 0 0
Other income (expense) (66,465) 393,918 21,416
Loss from continuing operations (5,915,558) (7,675,743) (9,643,351)
Gain on sale of discontinued operations 3,207,120 0 0
Net loss $(2,708,438) $(7,675,743) $(9,643,351)
Net loss per share from continuing
operations $ (0.57) $ (0.72) $ (0.58)
Net income per share from
discontinued operations 0.31 0.00 0.00
Net loss per share $ (0.26) $ (0.72) $ (0.58)
Weighted average number of shares
outstanding 10,296,812 10,657,311 16,550,915
</TABLE>

The accompanying notes are an integral part of the financial statements.

ANGEION CORPORATION
STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)

<TABLE>
<CAPTION>
CONVERTIBLE
PREFERRED STOCK COMMON STOCK ADDITIONAL
NUMBER NUMBER PAID-IN ACCUMULATED
OF SHARES PAR VALUE OF SHARES PAR VALUE CAPITAL DEFICIT TOTAL
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at July 31, 1992 0 $ 0 10,230,434 $102,304 $11,460,305 $ (7,158,200) $ 4,404,409
Stock issued at $4.00 per
share, net of issuance
costs 875,000 3,166,425 0 0 0 0 3,166,425
Stock options exercised 0 0 8,093 81 28,675 0 28,756
Director stock issued 0 0 68,698 687 215,288 0 215,975
Stock issued in settlement
of litigation 0 0 15,000 150 59,850 0 60,000
Compensation expense on
grant of options 0 0 0 0 40,219 0 40,219
Net loss 0 0 0 0 0 (2,708,438) (2,708,438)
Balance at July 31, 1993 875,000 3,166,425 10,322,225 103,222 11,804,337 (9,866,638) 5,207,346
Stock issued in connection
with merger of subsidiaries 0 0 663,610 6,636 1,443,863 0 1,450,499
Stock options exercised 0 0 115,530 1,155 4,222 0 5,377
Director stock issued 0 0 36,570 366 95,634 0 96,000
Stock issued for
consulting services 0 0 15,000 150 52,350 0 52,500
Compensation expense on
grant of options 0 0 0 0 67,301 0 67,301
Issuance of common
stock warrants 0 0 0 0 200,400 0 200,400
Net loss 0 0 0 0 0 (7,675,743) (7,675,743)
Balance at July 31, 1994 875,000 3,166,425 11,152,935 111,529 13,668,107 (17,542,381) (596,320)
Notes payable converted
into common stock 0 0 761,373 7,614 1,427,132 0 1,434,746
Stock and warrants issued
at $2.38 per share, net of
issuance costs 0 0 4,900,000 49,000 10,550,122 0 10,599,122
Stock options exercised 0 0 645,805 6,458 1,038,049 0 1,044,507
Director stock issued 0 0 40,416 404 95,596 0 96,000
Compensation expense on
grant of options 0 0 0 0 45,446 0 45,446
Net loss 0 0 0 0 0 (9,643,351) (9,643,351)
Balance at July 31, 1995 875,000 $3,166,425 17,500,529 $175,005 $26,824,452 $(27,185,732) $ 2,980,150
</TABLE>

The accompanying notes are an integral part of the financial statements.

ANGEION CORPORATION
STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
YEAR ENDED JULY 31,
1993 1994 1995
<S> <C> <C> <C>
Operating activities:
Net loss $(2,708,438) $(7,675,743) $(9,643,351)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation expense 287,084 322,873 385,453
Amortization expense 129,109 178,152 212,620
Expense on grant of stock and stock options 316,194 215,801 141,446
Notes payable discount amortization 0 33,000 100,200
Merger expense for in-process research and
development 0 1,450,499 0
Gain on sale of discontinued operations (3,207,120) 0 0
Changes in operating assets and liabilities:
Other receivable (6,094) (2,603) 38,697
Trade accounts receivable 77,615 0 0
Royalty receivable (217,756) 72,778 144,978
Inventories (81,954) (90,452) (168,577)
Prepaid expenses and other current assets 53,633 (62,886) (66,020)
Accounts payable (105,845) 101,903 366,776
Accrued expenses 117,614 305,158 (79,111)
Net cash used in operating activities (5,345,958) (5,151,520) (8,566,889)
Investing activities:
Payments for purchases of property and equipment (430,234) (244,254) (989,351)
Increase in other assets (523,185) (311,767) (337,158)
Net cash used in investing activities (953,419) (556,021) (1,326,509)
Financing activities:
Proceeds from issuance of preferred stock, net 3,166,425 0 0
Proceeds from issuance of convertible
subordinated debentures 1,500,000 0 0
Proceeds from sale of discontinued operations 6,409,315 0 0
Proceeds from exercise of stock options 28,756 5,377 1,044,507
Proceeds from sale of warrants 0 200,400 0
Proceeds from issuance of common stock and
warrants, net 0 0 10,599,122
Proceeds from issuance of notes payable 0 2,800,000 0
Repayments of debt (890,706) (12,911) (1,509,825)
Net cash provided by financing activities 10,213,790 2,992,866 10,133,804
Net increase (decrease) in cash and cash equivalents 3,914,413 (2,714,675) 240,406
Cash and cash equivalents:
Beginning of year 927,620 4,842,033 2,127,358
End of year $ 4,842,033 $ 2,127,358 $ 2,367,764
Supplemental disclosure of cash flow information:
Cash paid during the year for interest $ 22,310 $ 59,115 $ 240,031
</TABLE>

Supplemental disclosure of noncash investing and financing activities: During
1993, 15,000 shares of common stock valued at $60,000 were issued in
settlement of litigation.
During 1994, 15,000 shares of common stock valued at $52,500 were issued as
compensation for consulting services.
During 1995, $1,434,746 of notes payable were converted into common stock.

The accompanying notes are an integral part of the financial statements.

ANGEION CORPORATION
NOTES TO FINANCIAL STATEMENTS
YEARS ENDED JULY 31, 1993, 1994 AND 1995

1.DESCRIPTION OF BUSINESS

Angeion Corporation ("Angeion" or the "Company") designs, develops and
manufactures products that treat arrhythmias.

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

INVENTORIES: Inventories are stated at the lower of cost (determined on a
first in, first out basis) or market. Inventories consist primarily of
material costs.

PROPERTY AND EQUIPMENT: Property and equipment are carried at cost. Equipment
and furniture and fixtures are depreciated using the straight-line method over
five to seven years. Leasehold improvements are depreciated using the
straight-line method over the shorter of the lease term or useful life of the
asset. Expenditures for repairs and maintenance are charged to expense as
incurred.

PATENTS AND TRADEMARKS: The costs incurred to register patents and trademarks
are capitalized as incurred. Amortization of these costs commences when the
related patent or trademark is filed. The costs are amortized over the estimated
useful life of the patent or trademark, generally seven years.

INCOME TAXES: The Company accounts for income taxes under Statement of
Financial Accounting Standards No. 109, Accounting for Income Taxes.

NET LOSS PER SHARE: Net loss per share is computed by dividing net loss for the
period by the weighted average number of shares of common stock and common
equivalent shares outstanding during the period. Common equivalent shares
representing stock warrants and options were excluded for fiscal years 1993,
1994 and 1995 because of their antidilutive effect.

STATEMENTS OF CASH FLOWS: For purposes of the statements of cash flows, the
Company considers all highly liquid debt instruments purchased with a maturity
of three months or less to be cash equivalents.

3.MERGER OF SUBSIDIARIES

On December 20, 1993, AngeMed, Inc. ("AngeMed") and AngeLase, Inc. ("AngeLase"),
greater-than-90% owned subsidiaries of the Company, were merged with and into
the Company (the "Mergers"), with the Company being the surviving entity after
the Mergers. Pursuant to the Mergers, each share of common stock of AngeMed and
each share of common stock of AngeLase was converted into shares of Angeion
common stock. In addition, each option to purchase AngeMed or AngeLase common
stock was converted into an option to purchase Angeion common stock based upon
the respective exchange ratios.

Certain of the former AngeMed and AngeLase shareholders dissented from the
Mergers (the "Dissenters") and sought a higher value for the shares of AngeMed
and AngeLase common stock held by such shareholders in accordance with the
applicable provisions of Minnesota corporate law (the "Dissenters' Claims").
Effective May 31, 1994 and June 21, 1994, Settlement and Release Agreements were
entered into by and among the Company and the Dissenters (the "Settlement
Agreements"). Pursuant to the terms of the Settlement Agreements, the Dissenters
agreed to terminate their claims against the Company and the directors. In
exchange, the Company agreed to issue an aggregate of 636,004 shares of Angeion
common stock to the Dissenters in exchange for their subsidiary common stock and
to issue options to purchase Angeion common stock to the Dissenters in exchange
for their subsidiary options.

The fair market value of the common stock issued in connection with the Mergers
was accounted for as a purchase of in-process research and development and,
accordingly, a charge of $1,450,499 is included in the statement of operations
with an offsetting credit to shareholders' equity.

4.DISCONTINUED OPERATIONS

On September 22, 1992, the Company sold its Angeion Medical Products division
("AMP") effective as of July 31, 1992. Net sales of AMP were $6,777,346 in
fiscal 1992. The sale price consisted of $6.2 million cash at closing, plus a
royalty of 10% and 5% of AMP product sales in fiscal 1993 and 1994,
respectively. A gain of $3,207,120 (including $770,366 of royalties) was
recognized in 1993 and royalty income of $482,853 was recognized in fiscal 1994.
As of July 31, 1995, there are no further royalties to be recognized.

5.PROPERTY AND EQUIPMENT

At July 31 property and equipment consisted of the following:

<TABLE>
<CAPTION>
1994 1995
<S> <C> <C>
Production equipment $ 296,495 $ 630,953
Furniture and fixtures 117,465 177,365
Computer equipment 538,793 848,906
Research and development equipment 616,772 750,197
Leasehold improvements 187,071 338,526
1,756,596 2,745,947
Less accumulated depreciation and amortization (757,720) (1,143,173)
$ 998,876 $ 1,602,774
</TABLE>

6.ALLIANCE AND LONG TERM DEBT

On February 4, 1993, Angeion and Siemens Pacesetter, Inc. ("Pacesetter"),
which was subsequently acquired by St. Jude Medical, Inc. entered into an
agreement which provided for an investment by Pacesetter in Angeion and the
grant by Angeion of certain licensing, manufacturing and marketing rights with
respect to certain of the products being developed by the Company. The
investment by Pacesetter consisted of the purchase of 875,000 shares of Angeion
preferred stock, Class A, at $4.00 per share. The preferred stock is convertible
at any time on a one-for-one basis into common stock. Pacesetter's investment
also includes the purchase of a $1,500,000 convertible subordinated debenture
with an interest rate of 7.16%, interest payable semi-annually, which is
convertible at any time into common stock at $6.00 per share. The debenture is
due in semi-annual installments of $150,000, beginning July 1, 1998 through July
1, 2003.

7. NOTES PAYABLE

During June and July of 1994, the Company raised a total of $3,000,000 in the
form of short-term bridge loans ("Bridge Financing" or "Bridge Notes") to fund
its operations until it could complete an equity financing. All loans under the
Bridge Financing are evidenced by promissory notes accruing interest at a rate
of 12% per year. In connection with such loans, each lender received a warrant
to purchase, at an exercise price of $2.00 per share, shares of common stock
equal to 50% of the principal amount of the loan divided by the exercise price
of the warrant. The warrants expire on December 8, 1997. The warrants issued
were valued at $200,400 which was reflected as a discount and was amortized over
the term of the Bridge Notes. Certain directors of the Company participated in
the Bridge Financing and invested $1,000,000 in exchange for promissory notes
and warrants to purchase 250,000 shares. During September 1994, $1,434,746 in
Bridge Notes, net of discount, were converted into common stock and $1,500,000
in Bridge Notes were repaid.

8.PUBLIC OFFERING

On September 19, 1994, the Company completed a public offering of 4.9 million
shares of newly issued common stock and warrants to purchase one-half of a share
of common stock, which raised proceeds of approximately $10,600,000, net of
expenses. The exercise price of the warrants per whole share is $4.75 per share
and they expire in March 1996. Net proceeds from the sale of the securities are
being used for research and development, investment in capital equipment and
leasehold improvements, general corporate purposes, including working capital,
and for the repayment of unconverted short-term bridge loans.

9.SHAREHOLDERS' EQUITY

STOCK OPTIONS. The Company's shareholders have approved the 1993, 1991, 1989 and
1988 Stock Incentive Plans (the "Plans"). The Plans provide that incentive stock
options and nonqualified stock options to purchase shares of common stock may be
granted at prices determined by the Compensation Committee, except that the
purchase price of incentive stock options may not be less than 100% of the fair
market value of the stock at date of grant. All options expire not later than
ten years from date of grant.

In connection with the Mergers (Note 3), options under the AngeLase and AngeMed
Plans were converted into options to purchase common stock under the Plans.
Changes in options outstanding under the Plans are as follows:

<TABLE>
<CAPTION>
RANGE OF
SHARES OPTION PRICE
UNDER OPTION PER SHARE
<S> <C> <C>
Balance at July 31, 1992 1,270,121 $0.100-9.375
Granted in fiscal 1993 104,465 2.062-3.875
Exercised in fiscal 1993 0 --
Forfeited in fiscal 1993 (556,000) 1.560-9.375
Balance at July 31, 1993 818,586 0.100-9.062
Granted in fiscal 1994 818,296 1.970-3.500
Conversion of subsidiary
options 541,738 0.032-2.160
Forfeited in fiscal 1994 (115,530) 0.032-0.100
Forfeited in fiscal 1994 (54,000) 2.062-4.062
Balance at July 31, 1994 2,009,090 0.032-9.062
Granted in fiscal 1995 703,968 1.970-7.000
Exercised in fiscal 1995 (522,174) 0.032-5.000
Forfeited in fiscal 1995 (128,581) 0.032-3.875
Balance at July 31, 1995 2,062,303 $0.032-9.062
</TABLE>

Options for the purchase of 994,649 shares were exercisable at July 31, 1995.

The Company has granted options, outside the Plans, to purchase 272,063 shares
at prices ranging from $2.50 to $3.63 per share. At July 31, 1995, 222,063 of
these options were exercisable.

Options have also been granted under the Non-Employee Director Plan to purchase
63,000 shares at prices ranging from $2.44 to $3.19 per share. Under this plan,
annual stock grants of common stock valued at $16,000 are awarded to each
non-employee director.

WARRANTS. In connection with issuing a note payable to a shareholder in fiscal
1992, the Company issued a warrant to such shareholder to purchase 75,000 shares
of common stock at $2.50 per share. This warrant expires on July 27, 1999.

In connection with the Bridge Financing (Note 7), warrants to purchase 835,000
shares of common stock were issued at an exercise price of $2.00 per share.
These warrants expire on December 8, 1997.

In connection with a consulting agreement, warrants to purchase 40,000 shares
of common stock were issued, at an exercise price of $2.50 per share. These
warrants expire on December 15, 1998.

In connection with a public offering (Note 8), warrants to purchase 2,450,000
shares of common stock were issued at an exercise price of $4.75 per share.
These warrants expire on March 12, 1996. In addition, the placement agent for
the public offering was issued a warrant to purchase 490,000 shares of common
stock at $2.85 per share. This warrant expires on September 12, 1999.

10.LEASES

The Company leases office and production space under an operating lease. The
lease provides for executory costs which are subject to escalation based on
increases in the lessor's underlying costs. In addition, the Company leases
certain equipment under cancelable operating leases. Rent expense was
approximately $113,000, $116,000 and $138,000, for the years ended July 31,
1993, 1994 and 1995, respectively.

Future minimum lease payments under noncancelable operating leases (with initial
or remaining lease terms in excess of one year) are approximately $239,000,
$244,000 and $108,000 in 1996, 1997 and 1998, respectively.

11.INCOME TAXES

The Company has a tax net operating loss carryforward at July 31, 1995, of
approximately $25,000,000 which is available to reduce income taxes payable in
future years. If not used, this carryforward will begin to expire in 2004. Under
the Tax Reform Act of 1986, the utilization of these carryforwards may be
limited as a result of significant changes in ownership.

The actual tax expense (benefit) differs from the expected tax expense (benefit)
computed by applying the U.S. federal corporate income tax rate of 34.0% to the
net loss as follows:

<TABLE>
<CAPTION>
1993 1994 1995
<S> <C> <C> <C>
Federal statutory rate (34.0)% (34.0)% (34.0)%
State income taxes, net (6.0) (6.0) (6.0)
Expense on mergers of subsidiaries 0.0 6.4 0.0
Miscellaneous (1.7) 1.0 1.0
Change in valuation allowance 41.7 32.6 39.0
Effective income tax rate 0.0% 0.0% 0.0%
</TABLE>

Deferred taxes, calculated using an effective tax rate of 39.0% as of July 31
consist of the following:

<TABLE>
<CAPTION>
1994 1995
<S> <C> <C>
Net operating loss carryforwards $ 6,511,000 $ 10,200,000
Other 25,000 65,000
Total net deferred tax assets 6,536,000 10,265,000
Less valuation allowance (6,536,000) (10,265,000)
Deferred income taxes $ 0 $ 0
</TABLE>

The net deferred assets at July 31, 1994 and 1995, are fully offset by a
valuation allowance. The valuation allowance is reviewed annually.

12.RETIREMENT SAVINGS PLAN

The Angeion Corporation Tax Deferred Savings and Employees Stock Ownership Plan
(the "Plan") provides for contributions in the form of a salary reduction cash
or deferred arrangement, discretionary matching employer contribution,
discretionary supplemental employer contributions and voluntary after-tax
contributions by participating employees. Generally, all employees of the
Company who have completed six months of service with the Company are eligible
to participate in the Plan. Contribution expense was insignificant in all years
presented.

13.ROYALTY COMMITMENTS

The Company acquired the technology for its continuous-wave laser catheter
system. As part of this acquisition, the Company agreed to pay a royalty of 5%
on sales of patented products incorporating this technology for the life of any
patent on this technology. Additionally, in exchange for a doctor's efforts in
connection with the laser catheter ablation system, the Company has agreed to
pay the doctor and Carolinas Medical Center a royalty, when certain conditions
are met, of 2% and 3%, respectively, on all paid sales of laser ablation
devices. The Company has incurred no royalties through July 31, 1995, related to
the above commitment.

14.SUBSEQUENT EVENT

On August 2, 1995, the Company completed a public offering of 3.4 million shares
of newly issued common stock for proceeds of approximately $20,300,000, net of
expenses. During the nine months ended April 30, 1996 warrants that would have
expired on March 12, 1996 were exercised, along with certain stock options,
which provided to the Company net proceeds of approximately $12,800,000
(unaudited). The Company intends to apply the net proceeds of the sale of the
securities for research and development, investment in capital equipment and
leasehold improvements, and general corporate purposes, including working
capital.

ANGEION CORPORATION
CONSOLIDATED BALANCE SHEET
(UNAUDITED)

<TABLE>
<CAPTION>
APRIL 30,
1996
<S> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 14,789,510
Short-term investments 7,328,201
Receivables 401,913
Inventories 2,909,277
Prepaid expenses and other current assets 151,272
Total current assets 25,580,173
Property and equipment, net 3,667,445
Patents and trademarks, net 1,190,277
Other assets 135,073
Total assets $ 30,572,968
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 1,778,547
Accrued payroll, vacation and related costs 611,327
Current installments of capital lease obligations 984
Other accrued expenses 236,306
Total current liabilities 2,627,164
Long-term debt 1,500,000
Total liabilities 4,127,164
Shareholders' equity:
Convertible preferred stock, series A, $0.01 par
value.
Authorized 1,475,000 shares; issued and outstanding
875,000 shares at April 30, 1996 3,166,425
Common stock, $0.01 par value.
Authorized 35,000,000 shares; issued and
outstanding 24,212,207 shares at April 30, 1996 242,122
Additional paid-in capital 60,384,733
Accumulated deficit (37,347,476)
Total shareholders' equity 26,445,804
Total liabilities and shareholders' equity $ 30,572,968
</TABLE>

See accompanying notes to consolidated financial statements.

ANGEION CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

<TABLE>
<CAPTION>
NINE MONTHS ENDED APRIL 30,
1995 1996
<S> <C> <C>
Net sales $ 0 $ 874,959
Operating expenses:
Manufacturing expenses 0 2,278,242
Research and development 5,268,028 6,717,469
Sales and marketing 12,767 387,634
General and administrative 1,495,868 2,444,543
Total operating expenses 6,776,663 11,827,888
Operating loss (6,776,663) (10,952,929)
Other income (expense):
Interest income 245,354 878,879
Interest expense (141,848) (87,694)
Other income (expense) 103,506 791,185
Net loss $(6,673,157) $(10,161,744)
Net loss per share $ (0.41) $ (0.46)
Weighted average number of shares
outstanding 16,291,900 21,953,593
</TABLE>

See accompanying notes to consolidated financial statements.

ANGEION CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

<TABLE>
<CAPTION>
NINE MONTHS
ENDED APRIL 30,
1995 1996
<S> <C> <C>
Operating activities:
Net loss $(6,673,157) $(10,161,744)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation expense 274,369 478,826
Amortization expense 159,016 205,586
Compensation expense on grant of stock and stock
options 117,182 485,237
Notes payable discount amortization 83,500 --
Changes in operating assets and liabilities:
Receivables 183,675 (401,913)
Inventories 430 (2,510,489)
Prepaid expenses and other current assets 36,654 21,683
Accounts payable 135,001 942,246
Accrued expenses (129,843) 416,580
Net cash used in operating activities (5,813,173) (10,523,988)
Investing activities:
Purchase of short-term investments 0 (20,292,613)
Payments for purchases of property and equipment (803,289) (2,543,497)
Proceeds from maturities of short-term investments 0 12,964,412
Increase in other assets (281,234) (322,023)
Net cash used in investing activities (1,084,523) (10,193,721)
Financing activities:
Proceeds from issuance of common stock 10,599,122 20,327,045
Proceeds from exercise of stock options 381,192 1,184,779
Proceeds from exercise of warrants 0 11,630,337
Repayments of debt (1,508,999) (2,706)
Net cash provided by financing activities 9,471,315 33,139,455
Net increase in cash and cash equivalents 2,573,619 12,421,746
Cash and cash equivalents:
Beginning of period 2,127,358 2,367,764
End of period $ 4,700,977 $ 14,789,510
Supplemental disclosure of cash flow information:
Cash paid during the period for interest $ 160,533 $ 60,843
</TABLE>

Supplemental disclosure of non-cash investing and financing activities:

During the nine months ended April 30, 1995, notes payable of $1,434,746 were
converted into common stock.

See accompanying notes to consolidated financial statements.

ANGEION CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
APRIL 30, 1996

1.BASIS OF PRESENTATION

The unaudited interim consolidated financial statements include the accounts of
Angeion Corporation and its wholly-owned foreign subsidiary and have been
prepared by the Company in accordance with generally accepted accounting
principles, pursuant to the rules and regulations of the Securities and Exchange
Commission. Accordingly, certain information and footnote disclosures normally
included in financial statements have been omitted or condensed pursuant to such
rules and regulations. The accompanying unaudited interim consolidated financial
statements should be read in conjunction with the financial statements and
related notes included herein.

Effective November 1, 1995, the Company established a European subsidiary,
Angeion Europe Ltd. ("Angeion Europe"), to facilitate clinical trials of its
ICDs and expand its European business activities. The functional currency and
denomination of all sales transactions of Angeion Europe are the U.S. dollar.
Accordingly, the financial statements of Angeion Europe, which are maintained in
the local currency, are remeasured into U.S. dollars in accordance with
Statement of Financial Accounting Standards No. 52, "Foreign Currency
Translation." All exchange gains or losses from remeasurement of monetary assets
and liabilities that are not denominated in U.S. dollars are recognized
currently in income. For the nine-month periods ended April 30, 1995 and 1996,
the exchange gains recognized from remeasurement were $0 and $2,478,
respectively.

The information furnished reflects, in the opinion of the management of the
Company, all adjustments, consisting primarly of recurring accruals, considered
necessary for a fair presentation of the financial position and the results of
operations.

2.NET LOSS PER SHARE

Net loss per share is computed by dividing the net loss for the period by the
weighted average number of shares of common stock outstanding during the period.
Common equivalent shares representing stock warrants and options were excluded
in the fiscal 1995 and 1996 periods presented due to their antidilutive effect.

3.SHORT-TERM INVESTMENTS

In accordance with the provisions of Statement of Financial Accounting Standards
No. 115, "Accounting for Certain Investments in Debt and Equity Securities,"
marketable debt securities have been classified as held-to-maturity and are
stated at amortized cost, which approximates estimated fair value. Securities
held by the Company consist of U.S. government debt securities.

These securities are classified as held-to-maturity because of the Company's
positive intent and ability to hold its investments to maturity.

4.INVENTORIES

Inventories consisted of the following at April 30, 1996:

Raw materials $2,267,612
Work-in-process 543,759
Finished goods 97,906
$2,909,277

5.NON-CASH COMPENSATION

During the nine-month periods ended April 30, 1995 and 1996, the Company granted
in-the-money stock options and stock grants to employees, directors and
consultants in lieu of cash compensation, which amounted to $117,182 and
$485,237, respectively. For securities issued to employees, expense was
recognized for the stock and stock option grants based on the intrinsic value
method in accordance with APB Opinion No. 25, "Accounting for Stock Issued to
Employees." For stock issued to non-employees, expense was recognized based on
fair market value of securities granted.

6.CONTINGENCY

The Company has a pending employment legal proceeding that has arisen in the
ordinary course of business. It is the Company's opinion based on its review of
this matter with counsel that such proceeding will not have a material adverse
effect on the Company's financial position or results of operations.

7.PUBLIC OFFERING

On September 19, 1994, the Company completed a public offering of 4.9 million
shares of newly issued common stock and 4.9 million warrants to purchase
one-half of a share of Common Stock, which raised proceeds of $10,599,122 net of
expenses. The exercise price of the warrants per whole share was $4.75 per share
and they would have expired on March 12, 1996. Net proceeds of the sale of the
securities are being used for research and development, investment in capital
equipment and leasehold improvements, general corporate purposes, including
working capital, and for the repayment of unconverted short-term bridge loans.

On August 2, 1995, the Company completed a public offering of 3.4 million shares
of newly issued Common Stock for proceeds of $20,327,045 net of expenses. During
the nine months ended April 30, 1996 warrants that would have expired on March
12, 1996 were exercised, along with certain stock options, which provided to the
Company net proceeds of approximately $12,800,000. The Company intends to apply
the net proceeds of the sale of securities for research and development and
leasehold improvements, and general corporate purposes, including working
capital.

Inside Back Cover

3 part illustration of the procedure using catheter ablation device.
Illustration of patient and the insertion of catheter in femoral artery of leg
and up and into the heart. Cross section of heart depicting location of ablation
catheter and site of abnormal cells. Closeup of abnormal heart tissue in the
electrical pathways and the application of energy to the abnormal electrical
pathways.

An open lumen mapping catheter is inserted into the femoral artery in the leg
and threaded up and into the heart. The mapping catheter identifies the location
of cells causing the irregular heartbeat. An ablation catheter is threaded
through the opening of the mapping catheter. Radio frequency or laser energy
(depending on the location of the arrhythmia) is delivered to the site in the
heart tissue to eliminate the abnormal electrical pathways.

THE COMPANY'S PRODUCTS HAVE NOT BEEN APPROVED BY THE FDA AND THERE CAN BE NO
ASSURANCE THAT THE COMPANY WILL RECEIVE APPROVAL FROM THE FDA.

================================================================================

NO DEALER, SALESPERSON OR ANY OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED IN THIS PROSPECTUS IN
CONNECTION WITH THE OFFER MADE BY THIS PROSPECTUS AND, IF GIVEN OR MADE, SUCH
INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY THE COMPANY OR THE UNDERWRITERS. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER
TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OTHER THAN THE
COMMON STOCK TO WHICH IT RELATES, OR AN OFFER IN ANY JURISDICTION TO ANY PERSON
TO WHOM IT IS UNLAWFUL TO MAKE SUCH AN OFFER IN SUCH JURISDICTION. NEITHER THE
DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY
CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS
CORRECT AT ANY TIME AFTER THE DATE HEREOF.

TABLE OF CONTENTS

<TABLE>
<CAPTION>
PAGE
<S> <C>
Summary 3
Risk Factors 6
Use of Proceeds 13
Dilution 13
Capitalization 14
Dividend Policy 14
Market Price for Common Stock 15
Selected Financial Data 16
Management's Discussion and
Analysis of Financial Condition and
Results of Operations 17
Business 21
Management 35
Principal Shareholders and Beneficial
Ownership of Management 39
Description of Securities 41
Underwriting 44
Legal Matters 46
Experts 46
Available Information 46
Incorporation of Certain
Documents by Reference 47
Index to Financial Statements F-1
</TABLE>

4,200,000 SHARES

[ANGEION LOGO]

COMMON STOCK
P R O S P E C T U S
RAYMOND JAMES & ASSOCIATES, INC.
NATWEST SECURITIES LIMITED
SALOMON BROTHERS INC
JULY 1, 1996